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ABSTRACT OF DISSERTATION
ACTINOMYCIN FAMILIAL DIVERSITY DRIVEN BY PHENOXAZINONE-CORE
REACTIVITY
Actinomycins are a class of compounds consisting of phenoxazinone-like core
attached to two peptidolactone rings, denoted as α and β. A unique component of a few
families—actinomycins G, Y, and Z—is a chlorinated β-ring threonine residue. Families
G and Y also contained an actinomycin that possess a β-ring heterocycle (actinomycins G5
and Y5, respectively); prior to this work, no β-ring heterocycle-containing actinomycins
were reported for the Z family. Unlike other actinomycin derivatives, Y5’s cytotoxicity was
abolished while still maintaining some antibacterial potency.
We constructed a model compound to probe the physical properties of the
actinomycin core to test conditions under which heterocycle formation would occur. We
also analyzed the gene clusters of these actinomycin producers for gene candidates to from
this structural motif. We found the actinomycin core aniline to have pKa values of 2.976
and 8.429 and a significant shift in UV absorption between 300-310 nm when the group
becomes charged. We also found cyclization conditions and no obvious gene candidates to
form the β-ring heterocycle based on our gene cluster analysis. We hypothesize that the
familial diversity of the actinomycin G, Y and Z families is due to the reactivity of the
phenoxazinone-like core.
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Chapter 1: Introduction and Background
1.1 Actinomycin Discovery
The first actinomycin molecule to be discovered was actinomycin D in 1940 from
Streptomyces antibioticus.1 The organism was grown on agar media for 6-8 days, extracted
with ether, and then redissolved in 95% ethanol. The organic mixture was observed to be
a bright red color though maintained a yellow color even in concentrations as low as 1
µg/ml. Initial activity assays of actinomycin D showed it to be a quick and potent cytotoxic
agent while being slowly bactericidal against both Gram positive and Gram negative. Since
then, more than 30 naturally occurring actinomycin molecules belonging to approximately
nine different families have been discovered.2 The family an actinomycin molecule belongs
to is denoted by the letter following “actinomycin.” Actinomycins with identical α- and βrings are denoted as iso-actinomycin; those with differing α- and β-rings are known as
aniso-actinomycin.3,4 Figure 1.1.1 and Table 1.1.1 highlight many of the known structural
differences between several families of iso- and aniso-actinomycins.
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Figure 1.1.1-Actinomycin General Structure
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Structure of actinomycin D. Each amino acid member of the depsipeptide ring is
highlighted and the phenoxazinone-like core is shown in black to denote the different areas
of the actinomycin scaffold. Within the core, the aniline bound to position 2 will be denoted
as “2-NH2” henceforth.
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Table 1.1.1-Select Modifications to Actinomycin General Structure
Cmpd
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4-OH-Pro

Gly

Val

F8

Thr

D-Val

Gly

Gly

Val

Thr

D-Val

Gly

Gly

Val

F9

Thr

D-Val

Gly

Gly

Val

Thr

D-Val

Pro

Gly

Val

X2

Thr

D-Val

Pro

Gly

Val

Thr

D-Val

4-Oxo-Pro

Gly

Val

C2

Thr

D-Val

Pro

Gly

Val

Thr

D-Ile

Pro

Gly

Val

C3

Thr

D-Ile

Pro

Gly

Val

Thr

D-Ile

Pro

Gly

Val

Y1

Thr

D-Val 3-OH-5-Me-Pro

Gly

Val

4-Cl-Thr

D-Val

4-Oxo-Pro

Gly

Ala

Y2

Thr

D-Val 3-OH-5-Me-Pro

Gly

Val

4-Cl-Thr

D-Val

4-OH-Pro

Gly

Ala

Y3

Thr

D-Val

3-OH-5-Me-Pro

Gly

Val

rThr

D-Val

4-Oxo-Pro

Gly

Ala

Y4

Thr

D-Val

3-OH-5-Me-Pro

Gly

Val

rThr

D-Val

4-OH-Pro

Gly

Ala

Y5

Thr

D-Val 3-OH-5-Me-Pro

Gly

Val

cNHThr

D-Val

4-Oxo-Pro

Gly

Ala

G2

Thr

D-Val 3-OH-5-Me-Pro

Gly

Val

4-Cl-Thr

D-Val

Pro

Gly

Ala

G3

Thr

D-Val

3-OH-5-Me-Pro

Gly

Val

4-OH-Thr

D-Val

Pro

Gly

Ala

G4

Thr

D-Val 3-OH-5-Me-Pro

Gly

Val

Thr

D-Val

Pro

Gly

Ala

G5

Thr

D-Val 3-OH-5-Me-Pro

Gly

Val

cOThr

D-Val

Pro

Gly

Ala

G6

Thr

D-Val 3-OH-5-Me-Pro

Gly

Val

rThr

D-Val

Pro

Gly

Ala

Z1

Thr

D-Val 3-OH-5-Me-Pro

Gly

Val

4-OH-Thr

D-Val 4-Oxo-5-Me-Pro

Gly

Ala

Z3

Thr

D-Val 3-OH-5-Me-Pro

Gly

Val

4-Cl-Thr

D-Val 4-Oxo-5-Me-Pro

Gly

Ala

Z5
Neo Act A
Neo Act B

Thr

D-Val

5-Me-Pro

Gly

Val

4-Cl-Thr

D-Val 4-Oxo-5-Me-Pro

Gly

Ala

Thr
Thr

D-Val
D-Val

Pro
Pro

Gly
Gly

Val
Val

Thr
Thr

D-Val
D-Val

Gly
Gly

Ala
Ala

Pro
Pro

The structural components of each actinomycin used whose bioactivity is listed in Table
1.3.1
rThr: β-ring threonine rearranged to produce unique β-ring core structure
cO: Oxygen is the heteroatom between 1b and 2-NH2 involved in a β-ring heterocycle
cNH: Amine group is the heteroatom between 1b and 2-NH2 involved in a β-ring
heterocycle
Neo Act A: Contains a methyl oxazole ring formed at core positions 2 and 3
Neo Act B: Contains a carboxyethyl oxazole ring formed at core positions 2 and 3
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1.2 Actinomycin Mechanism of Action
Actinomycins have three accepted mechanisms of inducing cell death: intercalation
into pre-melted GC-rich DNA inhibiting mRNA transcription, the transfer of reactive
oxygen species to the DNA backbone resulting in irreversible damage, and the inhibition
of topoisomerase I and II.5,6,7,8 The second of these mechanisms is unlikely to be clinically
relevant due to the required concentration to observe the formation of actinomycin’s
radical-induced DNA damage; the generation of free radicals requires the an actinomycin
concentration of ~10-4 M whereas the concentration of actinomycin required to inhibit
DNA transcription is ~10-8 M.5 Actinomycin’s ability to stimulate double-stranded DNA
breaks via inhibition of DNA topoisomerases I and II is also observed at a higher
concentration (1-3 µM) than that required to inhibit DNA transcription.9 However, the
identification of this class of compound’s ability to form radical species and inhibit
topoisomerases at all could be relevant in the future diversification of this molecule and
could be a secondary mechanism of action for actinomycins that appear to be poor DNA
intercalators.
The first of these mechanisms has been extensively studied in previous work.
Actinomycin D has been crystallized with DNA showing the phenoxazinone core
preferentially intercalated in between the guanine and cytosine residues of the DNA
double-helix (Figure 1.2.1).10 A strong hydrogen bond is present between the amide N-H
of amino acid 2 (usually valine) and the carbonyl of amino acid 5 (usually valine or alanine)
within the same α or β ring to provide the peptidolactone rings with additional rigidity.11
This rigidity helps align the threonine residue of each ring (amino acid 5) with the guanine
residue of the DNA backbone; between these two residues, two hydrogen bonds exist
4

between the guanine 2-amino group and the threonine carbonyl as well as between the
guanine N(3) nitrogen and the amide N-H of the threonine residue.11 It is likely these
hydrogen bonds and the pi-orbital stacking interactions that confer actinomycin’s
specificity to GC regions of DNA12,13 However, hydrogen bonding between acintomycin,
the DNA backbone, and water are much larger contributors to the overall stability of the
DNA-actinomycin complex. This structure is stabilized by a total of 152 hydrogen bonds,
80% of which involve an interaction with water; notable exceptions of this complex that
could but do not participate in hydrogen bonding are the N(7) imidazole nitrogen of
guanosine and the carbonyl of amino acid 5 in each peptidolactone ring.11 In this complex,
the peptidolactone rings rest in the DNA minor groove.14
The stabilization of this actinomycin-DNA complex helps to inform the mechanism of
action. Early experiments exploring actinomycin’s relationship to cell toxicity found that
actinomycin bound to DNA and inhibited RNA synthesis by interfering with the growing
mRNA from RNA polymerase7,15,16,17,18. Implicit in this proposed mechanism was that
actinomycin would bind to the most common and available form of DNA, B-DNA.19
Though actinomycin can bind to B-DNA, it binds more tightly to one chain more tightly
than another due to approximate two-fold symmetry; x-ray crystallography of

the

actinomycin D-DNA complex showed that the phenoxazinone-like chromophore is slightly
twisted like a propeller.11,14 This led Sobell to conclude that actinomycin binds to premelted DNA—or β-DNA—at the premelton, preventing RNA polymerase from moving.14
This explanation also reveals how actinomycin can interfere with mRNA chain elongation
without inducing premature mRNA chain termination7.
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Figure 1.2.1-Stereoviews of Actinomycin D Binding to DNA

Stereoviews of the actinomycin D-DNA complex. (A) Viewing into the DNA minor
groove. (B) Viewing into the DNA minor groove but rotated 90o along the axis of the
helix.20
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1.3 Structure-Activity Relationships of Modifications the Actinomycin D
The biological activity of various actinomycins has been investigated since the
discovery of actinomycin D.1 However, scientific standards and practices have changed in
the nearly 80 years since that discovery; as such, it is very difficult to make direct
comparisons between different actinomycin congeners that have been tested against
different cell lines using differing measurement techniques. Table 1.3.1 attempts to
standardize the activities of 20+ naturally occurring actinomycins by comparing their
activity to actinomycin D in the same cell type using the same measurement technique.
From this and other synthetic derivatives of actinomycin, we can draw an informed picture
of the structure-activity relationships (SAR) of how various chemical moieties effect the
activity of the actinomycin scaffold.
As discussed in Section 1.2, actinomycin’s mechanism of action does not utilize
the formation of a covalent bond to DNA nor does the binding to DNA change
actinomycin’s covalent structure. Its dominant biological activity is determined by (1) the
intercalation of the phenoxazinone core between GC base pairs of DNA and (2) the
stabilization of that intercalation in the DNA minor grove via hydrogen bonding between
the actinomycin peptidolactone rings and the DNA backbone.5, 11, 14
In previous SAR studies, sites around the phenoxazinone core have been altered to
determine their necessity to the biological activity. It was found that the replacement of the
2-amino group of the phenoxazinone core (2-NH2) with a hydrogen, hydroxyl, or chloro
group abolished biological activity;21-24 alkylation or acylation at this site reduces the
activity by 10-fold relative to actinomycin D.22-23 In the case of the recently discovered
neo-actinomycins, the addition of TCA cycle intermediates to form the tetracyclic 5H7

oxazolo[4,5,b] phenoxazinone chromophore reduces the cytotoxicity by 1000-fold and
reduces the antibacterial potency by 100-fold.2 It is clear from this collective data that the
2-NH2 position of the phenoxazinone core requires at least one hydrogen bond donor to
show any measurable activity. It is also clear that disruption to the planar nature of the core
via attachment of alkyl chains (as is the case in several synthetic derivatives and the neoactinomycins) greatly reduces the activity of the actinomycin derivative.2, 22-23
Other changes to the phenoxazinone chromophore have also been investigated in
SAR studies. Replacement of the methyl groups at the 4- and 6- position with hydrogens
or methoxy groups slightly reduces the biological activity but replacement of the methyl
groups with the similarly sized CF3 groups eliminates the activity of the actinomycin
derivative, likely due to pulling electronic density away from the aromatic ring system,
reducing the ability of the molecule to pi-stack with the GC-DNA base pairs.25-26
Replacement of these methyl groups with bulkier ethyl groups reduced activity by 30-35%
while replacement with tert- butyl groups abolished activity;25 these changes are likely the
result of the addition of steric bulk and the disruption of the planar nature of the
actinomycin core which prevents the molecule from intercalating between DNA base pairs.
Furthermore, addition of groups to the 7-position of the phenoxazinone core has been
investigated. 7-chloroactinomycin and 7-nitroactinomycin show ~50% reduced
antimicrobial activity when compared to actinomycin D but 7-bromoactinomycin showed
~50% greater activity; all showed comparable antitumor activity to actinomycin D in
vivo.27-28 This shows not only that this is perhaps a good site to create actinomycin
derivatives but also provides additional evidence that actinomycins can behave differently
in bacteria than in mammalian cells.
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Several modifications to the peptidolactone rings have also been investigated.
Swapping the Thr (1a, 1b) residue for a Ser, diaminoproprionic acid, or diaminobutyric
acid displays ~10% of the antibacterial activity and ~10 fold lower antitumor activity than
actinomycin D.29-31 Replacement of the proline residue with pipecolic acid yields
actinomycins with little change in activity.32 Replacement of both methyl valine (5a, 5b)
residues with methyl leucine produces activity ten times greater than actinomycin D; this
increase in activity is thought to be caused by more hydrophobic interactions between the
actinomycin derivative and DNA.33 Symmetry of the molecule does not appear to correlate
with activity. However, the oxidation state of the amino acids in the peptidolactone chains
do. Actinomycins with a hydroxyl-proline residue—such as actinomycin Y2—show ~1000
fold decrease in efficacy, likely due to these molecules inability to easily diffuse past the
cellular membrane.34-35 Actinomycins with a hydroxyl-β-threonine residue (1b)—such as
actinomycins Z1 and G3—also showed significantly decreased activity, likely for the same
reason.36-37 The inclusion of a 4-chlorothreonine residue at 1b does not appear to positively
or negatively affect biological activity.34-36 To date, no sole threonine (1a) modification in
the α-ring has been discovered or synthesized.
Finally, the actinomycin G and Y families contain members with unique structures.
Both contain a rearranged β-ring resulting in the formation of a true cyclopentapeptide that
is present in actinomycins G6, Y3, and Y4.35 This type of rearrangement all but abolishes
the cytotoxicity and antibacterial activity of these molecules. These two families also
contain actinomycins with β-ring heterocycles which link the group at the 2-NH2 position
with the protruding methyl group from Thr 1b. In the case of actinomycin G5, the
heteroatom that links these positions is an oxygen; this particular structure renders the
9

actinomycin molecule weakly cytotoxic and a poor antibiotic.36 However, in actinomycin
Y5, the heteroatom is a nitrogen; this change appears to completely remove any measurable
cytotoxicity from the molecule but also appears to alter the molecule’s antibacterial activity
to make it only 30% less effective than actinomycin D or Y1.35 The activities of these
molecules—G5, G6, Y3-4, and Y5—are of particular interest to this work due to their
extreme divergence from the core actinomycin scaffold as well as their unique activity,
especially in the cases of G5 and Y5.
This is not an exhaustive examination of all SAR studies done to the actinomycin
scaffold. It allows for the ability to draw some conclusions about modifications that can
increase and decrease the biological activity of actinomycins. These conclusions also help
reinforce the mechanism of action for the actinomycin scaffold.
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Table 1.3.1-Selected Actinomycins and their Biological Activity as Compared to
Actinomycin D
Compound Cytotoxicity Antibacterial
Act D

1.00E+00

1.00E+00

X0β

1.00E-01

2.50E-01

F8

1.00E-01

4.50E-01

F9

5.00E-01

3.50E-01

X2

8.00E+00

2.00E+00

C2

1.00E+00

7.00E-01

C3

7.00E-01

9.50E-01

Y1

1.07E+00

1.00E+00

Y2

9.41E-04

6.00E-01

Y3

1.60E-03

6.43E-04

Y4

1.60E-04

6.43E-04

Y5

1.60E-04

7.33E-01

G2

1.23E+00

9.00E-01

G3

1.23E-02

9.00E-01

G4

2.46E-02

n/a

G5

7.62E-04

3.70E-01

G6

1.60E-03

0.00E+00

Z1

2.13E-03

6.24E-02

Z3

1.60E-02

3.90E+00

Z5

1.60E-02

1.00E+00

Neo Act A
Neo Act B

2.45E-03
2.80E-04

1.56E-02
1.95E-03

Value calculated as a ratio of activity to actinomycin D. Values >1.00E+00 show
greater activity relative to actinomycin; values <1.00E+00 show less activity relative to
actinomycin. Denotes a ratio of cytotoxicity and antibacterial activity relative to
actinomycin D. Unknown cell lines tested for cytotoxicity and antibacterial activity.38
Denotes a ratio of GI50 (µg/mL) relative to actinomycin D in HM02 colorectal cancer
cells.35 Denotes a ratio of IC50 (nM) relative to actinomycin D in HCT116 gastrointestinal
carcinoma.2 Denotes a ratio of inhibition zone size (mm) from 50 µg dissolved onto a 6
mm disk placed on a lawn of Staphylococcus aureus relative to actinomycin D.2, 35 Denotes
ratio of MIC (µg/mL) values relative to actinomycin D in Bacillus subtilis.34
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1.4 Current Uses of Actinomycin
Actinomycin D is clinically known as Dactinomycin and is marketed under the
trademark Cosmegen. Its current clinical applications are to treat Wilms’ Tumor, childhood
Rhabdomyosarcoma, metastatic nonseminomatous testicular cancer, Ewing’s Sarcoma,
gestational trophoblastic neoplasia, and regional perfusion in locally recurrent and
locoregional solid malignancies through intravenous injection .39 Its half-life in a dog is 47
h with a distribution phase of 3 h.40 Though actinomycin shows efficacy against grampositive bacteria, gram-negative bacteria, and some fungi, its toxicity precludes it from
being clinically approved to treat these types of infections.41 It is believed that the
mechanism of resistance to actinomycins is the development of a multidrug resistant
phenotype due to the increased production of P-glycoproteins and other xenobiotic
channels as well as decreased membrane permeability.40
The current dosing regiments for the various disease state treated by actinomycin
D are as follows for adults42:
-Wilms Tumor, 45 µg/kg IV every 3-6 weeks for up to 26 weeks
-Rhabdomyosarcoma, 15 mg/kg IV on days one and five every 3-9 weeks for up to
112 weeks
-Ewing Sarcoma, 1250 µg/m2 IV once per three weeks for 51 weeks
-Gestational Trophoblastic Neoplasms, 12 µg/kg IV once per day for five days as a
single agent for nonmetastatic and low-risk metastatic disease, 500 µg/kg IV on days one
and two once every two weeks for up to 8 weeks for high-risk metastatic disease
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-Testicular cancer, 1000 µg/kg IV once every three weeks for 12 weeks as part of
a cisplatin-based, multiagent combination regimen
-Locoregional solid malignancies, 50 µg/kg IV once in combination with
melphalan for lower extremity and pelvis malignancies, 35 µg/kg IV once in combination
with melphalan for upper extremity malignancies
-Malignant germ cell tumors of the ovary (off label), 300 µg/m2/day IV for 5 days
once every four weeks in combination with vincristine and cyclophosphamide
The cost per injection of actinomycin D (under the brand name Cosmegen) is estimated at
$1,283.43
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1.5 Gene Cluster of Actinomycin
The gene clusters between families of actinomycin can vary greatly in gene number but
can vary subtly in gene product. For example, the gene cluster for actinomycin X—an isoactinomycin—sequenced from Streptomyces antibioticus IMRU 3720, contains 20 coding
DNA sequences (CDSs) spanning 37.5 kb; contrastingly, the gene cluster for actinomycin
C—another iso-actinomycin—sequenced from Streptomyces chrysomallus, contains 28
CDSs spanning 47.8 kb.44-45 The gene cluster found in Streptomyces antibioticus IMRU
3720 represents the minimal manufacturing machinery required to produce an actinomycin
molecule (Table 1.5.1).45 The discrepancy in size between the two gene clusters stems
from the presence of eight doubly occurring orthologues in the actinomycin C gene cluster
expressed under a second promoter.45 The expansion of the actinomycin gene cluster
appears to have been caused by a mobile genetic element from a foreign actinomycin
cluster instead of a duplication of the same genes within a cluster; supporting this
hypothesis are the insertion sequences (IS) found flanking the gene cluster of actinomycin
C and a 2.5% difference in G+C content between orthologues within the gene cluster.45-46
Furthermore, although the two gene clusters contain the same genes, they produce two
subtly different types of actinomycin, implying that some of the transposed genes are
inactive.45
Though the discovery that the expansion that the actinomycin gene cluster was
likely due to IS elements, its effects may have been observed for some time in the form of
aniso-actinomycins. For example, actinomycins from the G, Y, and Z (whose gene clusters
will be discussed in greater detail in Chapter 3) families all have similar modifications to
their α- and β-rings but differ in how those modifications are combined between rings.3414

35, 47

This could have been caused by the mutation and transposition of actinomycin gene

cluster elements that originated from different actinomycin gene cluster donors.
Furthermore, the G, Y, and Z families all contain a 4-chlorothreonine unit in the
actinomycin β-ring.34-36 Likely, genes associated with this type of modification were also
added to the cluster via IS element. However, it is unclear if each of these insertions was
made in the same way, which might have led to some gene inactivation/mutation and
explain some of the β-ring variability among the G, Y, and Z family members, specifically.
This orientation is visualized in Figure 1.5.1. The gene clusters from these family members
also contain six non-ribosomal peptide synthetase genes as opposed to the normal four
observed in Streptomyces anulatus and antibioticus.47 This expansion of NRPS machinery
could explain the biosynthesis and combination specificity of actinomycin α- and β-rings
observed in aniso-actinomycin families.
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Table 1.5.1-Annotated Actinomycin Gene Cluster from Streptomyces antibioticus
Gene
orthologues in S.
chysomallus acm
gene cluster
left/right arm

Protein %
Identity to
S.
chysomallus
orthologue

Protein %
similarity to
S.
chrysomallu
s orthologue

Genes in S.
antibioticus

Predicted
Function

AFM16_363
45

α/β hydrolase

AFM16_363
50

Ser/Thr protein
kinase

saacmrC

UvrA-like
protein

scacmcrC/scacm
Y

87/83

92/90

saacmrB

ABC 2-type
transporter

scacmrB/scacmX

89/85

95/92

saacmrA

ABC
transporter
ATPase subunit

scacmrA/scacm
X

86/83

92/89

saacmQ

Siderophoreinteracting
protein

scacmQ/scacmV

82/79

89/90

saacmP

TetR family
transcriptional
regulator

scacmP/scacmU

77/66

83/72

saacmO

LmbU-like
protein

scacmO/scacmJ

77/71

84/78

saacmN

Ferredoxin

scacmN

73

83

saacmM

Cytochrome
P450

scacmM

86

90

saacmL

Methyltransfer
ase

scacmL/scacmI

88/82

93/88

saacmK

Kynureninase

scacmK/scacmH

84/82

89/92
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saacmG

Tryptophan
2,3-dioxygenase

scacmG

78

82

saacmF

Aryl
formamidase

scacmF

82

86

saacmE

Hypothetical
protein

scacmE

82

89

saacmC

Peptide
synthetase
ACMS III

scacmC

76

83

saacmB

Peptide
synthetase
ACMS II

scacmB

72

81

saacmA

Peptide
synthetase
ACMS I

scacmA

75

84

saacmD

4-MHA carrier
protein
AcmACP

scacmD

75

87

saacmR

MbtH-like
protein

scacmR

80

90

saacmS

Hypothetical
protein

scacmS

74

85

saacmT

Hypothetical
protein

scacmT

73

84

AFM16_364
55

Putative alpha1,2mannosidase

AFM16_364
60

Threonine
transporter
RhtB

Putative gene cluster for actinomycin D and its relationship to homologues found in the
actinomycin C gene cluster
Abbreviations:
ACMS
methylanthranilic acid.

(actinomycin
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synthetase),

4-MHA

(3-hydroxy-4-

Figure 1.5.1-Visualized Actinomycin C, G, and Y Gene Clusters

Figure adapted from Wang et al.47 Genes denoted AcmG6-AcmG9 in the actinomycin G
gene cluster and Y14-Y17 appear to be transcribed in the opposite direction of the genes
with which they are believed to associate.
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1.6 Biosynthesis of Actinomycin
The biosynthesis of actinomycins has been largely elucidated, though the identity of
the enzymes responsible has not yet been confirmed for every step. To synthesize the
initiation unit for the NRPS assembly line, tryptophan is first converted to 4-methyl-3hydroxyanthranilic acid (4-MHA).48 The first step in the biosynthesis of this piece is the
oxidation of tryptophan to N-formylkynurenine catalyzed by tryptophan 2,3-dioxygenase
followed by removal of the formyl group catalyzed by kynurenine formidase to form
kynurenine.49-50 This intermediate is then hydroxylated by a kynurenine 3-hydroxylase
before being converted to 4-methyl-3-hydroxyanthranilic acid catalyzed by kynureninase
and a methyl transferase.51-52 This biosynthetic mechanism follows a similar one found to
produce part of nicotinamide adenine dinucleotide (NAD), an essential coenzyme involved
in redox chemistry in all cells.51 However, no one-pot enzymatic reaction has been
performed to confirm if these are all of the enzymes required to produce 4-MHA, though
it is accepted within the literature that this is the biosynthetic scheme used by Streptomyces
sp. in the construction of actinomycins. (Figure 1.6.1)
The peptide halves of the actinomycin molecule are synthesized like other nonribosomal peptides. The thiolation domain (T; also known as a peptidyl-carrier protein
abbreviated “PCP”) of each NRPS module is first converted from its inactive “apo” form
to its active “holo” form by the addition of a 4-phosphopantetheinyl (PPant) group to the
active site serine. After post-translational modification, a stable thioester bond is formed
between the T domain and the amino acid selected by the adenylation (A) domain. The
thioester-linked amino acid is subsequently combined with another T-domain-bound
amino acid from an adjacent module via nucleophilic attack catalyzed by the condensation
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(C) domain that lies between them. This combination often results in the creation of an
amide bond. The peptide continues to grow in this way by being passed from module-tomodule in an assembly-line fashion, receiving one additional amino acid from each Tdomain, until it is cleaved from the NRPS enzyme complex via internal cyclization or
reduction by the thioesterase domain (TE).53-54 This complex can also contain tailoring
domains—such as methylation, epimerization, and redox domains—to form non-canonical
amino acids.54-55
In the case of actinomycin, once the 4-MHA unit has been synthesized, it is loaded onto
ACMS I (saacmA in Table 1.5.1) via activation with adenosine triphosphate (ATP) before
being transferred to the 4-MHA carrier protein (saacmD in Table 1.5.1).56-57 These two
genes represent the “loading domain” of an NRPS assembly line. The 4-MHA starter unit
is then passed to ACMS II (saacmB in Table 1.5.1) where it is linked to L-threonine and
L-valine (later epimerized to D-valine via the ACMS II epimerization domain).58-60 The
growing peptide chain is then shuttled to ACMS III (saacmC in Table 1.5.1) where it is
linked with L-proline, sarcosine (N-methylated glycine), and N-methyl-L-valine; the
completed pentapeptide is cleaved from ACMS III via internal lactone cyclization
catalyzed by the thioesterase domain between the threonine hydroxyl group and the
thioester-bound N-methyl-L-valine.58,

61

Two of the cleaved depsipeptide rings are

combined by a phenoxazinone synthetase (PHS), although no homologue lies within the
actinomycin gene cluster.62 It is hypothesized that gene the encoding this enzyme lies
outside of the gene cluster, perhaps in the phenazinomycin gene cluster, which has also
been found in some actinomycin-producing Streptomyces sp.63 This biosynthesis is
depicted in Figure 1.6.2 and 1.6.3.
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As previously mentioned, aniso-actinomycins deviate slightly in their biosynthesis
from the process described above. Due to the insertion of actinomycin biosynthetic
machinery from another actinomycin gene cluster, these aniso-producing strains have the
ability to produce two different depsipeptide rings—using the same generic NRPS
chemical logic previously described—that are combined in a 1:1 ratio. It is unclear if the
additional oxidations, methylations, and halogenations observed in the G-, Y-, and Zfamilies occur before the amino acids are loaded onto the NRPS assembly line, while the
growing peptide chains are attached to the assembly, or after the phenoxazinone synthetase
has united the α- and β-rings.34-37,

47

However, a new NRPS domain—called the X-

domain—was recently discovered and shown to facilitate the recruitment of various
tailoring enzymes to the NRPS assembly line.64 Perhaps, these families possess a
homologue to this domain, though we think such a domain is not responsible for β-ring
heterocycle formation based on actinomycin core reactivity that is explored in Chapter 2.
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Figure 1.6.1-Biosynthesis of 4-methyl-3-hydroxyanthranilic acid in Actinomycin
Pathway

NH2

NH2
OH
O

NH2
OH

(1)
O
NH

N
H

O

OH

(2)
O
NH2

H
O

O

(3)
NH2

CH3
OH

OH

(4)*

O
NH2

NH2

O

OH

OH

Biosynthetic pathway for the generation of 4-methyl-3-hydroxyanthranilic acid (4-MHA).
The enzymes associated with each numbered step are listed below:
(1)
(2)
(3)
(4)

Tryptophan 2,3-dioxygenase (EC 1.13.11.11)
Kynurenine formamidase (EC 3.5.1.9)
Kynurenine 3-hydroxylase (EC 1.14.13.9)
3-hydroxy-kyreninase/kynureninase (EC 3.7.1.3) and C-methyltransferase (no
enzyme commissioner number listed); *likely in this order
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Figure 1.6.2-Visualized Assembly-line Construction of Actinomycin D on NonRibosomal Peptide Synthetase

Biosynthetic assembly of each half of actinomycin D on the Non-Ribosomal Peptide
Synthetase. The enzyme domain legend is listed below:
A: Adenylation Domain
T: Thiolation Domain (peptidyl-carrier protein abbreviated “PCP”)
C: Condensation Domain
E: Epimerization Domain
M: Methylation Domain
Te: Thioesterase Domain
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Figure 1.6.3-Proposed Final Step in Actinomycin Biosynthesis
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Combination of the identical halves of actinomycin D by phenoxazinone synthetase. To
date, the gene responsible for this unification has not be elucidated within the actinomycin
gene cluster.
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Chapter 2: Synthesis of Phenoxazinone-Like “Actinocin” Core and Determination
of Its Physical Properties
2.1 Introduction
Previously, it was speculated that the β-ring heterocycle observed in actinomycin
Y5 was formed via an intramolecular SN2-style reaction.35 However, it was our belief that,
if this were the mechanism of heterocycle formation, this structural motif would be more
prevalent within the actinomycin Y family. Furthermore, based on the aromatic
environment in which the proposed nucleophile existed, it was unclear just how reactive
this phenoxazinone-core aniline (position 2-NH2 in Figure 1.1.1) would be.65
We decided to test the reactivity of this position by building a model system. We
chose to approximate “reactivity” by determining the pKa of the phenoxazinone-core
aniline by exposing it to a variety of pH conditions due to our assumption that if the electron
density of this particular aniline group were available to make a nucleophilic attack from
2-NH2 to Thr 1b in Figure 1.1.1, it would also be available to donate/accept a proton and
because the pKa of the molecule aniline is 4.63.65 We felt this was appropriate because pH
is related to pKa through the Henderson-Hasselbach equation and because pKa itself
denotes the equilibrium constant between an acid and its conjugate base, providing a
quantitative value for the conditions under which this chemical reaction occurs.66
Should the 2-NH2 of methyl actinocin prove reactive, we would try several reaction
conditions attempting to alkylate that position. The goal was to attempt to recreate the type
of intramolecular alkylation that would have to occur in β-ring heterocycle containing
actinomycins if the structural motif were formed via this SN2 mechanism.
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2.2 Methods
Experiments confirmed by LC/MS in this chapter were done so utilizing an Agilent Eclipse
XDB-C18 10mm column attached to an Agilent Technologies 6120 Quadrupole LC/MS.
The gradient used was 0.4 mL/min flow rate beginning with a ratio of 95:5 water:
acetonitrile, increasing to 0:100 water: acetonitrile over 16 min. This ratio was held for
four minutes before reverting back to a 95:5 water: acetonitrile ratio over the next minute.
This ratio was held for the remaining four minutes.
Synthesis of Methyl Actinocin
The total synthesis of our model is depicted in Figure 2.2.1(a) (1) 3-hydroxy-4methyl nitrobenzoic acid (0.25g) was dissolved in 20 mL of anhydrous methanol in a 50
mL round bottom flask. Two mL of thionyl chloride was added dropwise with stirring. The
mixture was heated to 60oC under a reflux condenser and left to react overnight. The
product, 3-hydroxy-4-methyl-2-nitrobenzoic acid methyl ester, was extracted by adding
ethyl acetate and washing the organic layer mixture twice with saturated sodium
bicarbonate, twice with brine, and once with water. The organic layer was dried with
sodium sulfate and concentrated in vacuo.
(2) To a clean, dry 50 mL double-necked round bottom flask, a few spatulas of
palladium on activated carbon were added. The flask was then sealed and the air was
removed and replaced by nitrogen gas. 3-hydroxy-4-methyl-2-nitrobenzoic acid methyl
ester was dissolved in 20 mL anhydrous methanol and injected into the sealed flask.
Hydrogen gas was then bubbled into the mixture at room temperature. The reaction was
left under hydrogen gas for 48 hours. The palladium on activated carbon was removed by
vacuum filtration through celite.
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(3) The resulting 2-amino-3-hydroxy-4-methylbenzoate was dissolved in 20 mL
methanol. Then, 1.10g of potassium ferricyanide was dissolved into 0.067M potassium
phosphate buffer and added to the mixture followed by the addition of 1.4 mL of 2M
sodium hydroxide to adjust the pH to ~8. The solution was wrapped in foil and placed
under nitrogen balloon for 16 h. To extract the organic product, ethyl acetate and water
were added and the organic layer was extracted. The organic layer was washed with brine
and then dried with sodium sulfate before being concentrated in vacuo. The resulting redorange solid was then subjected to a flash chromatography column (3:1 hexanes:ethyl
acetate) to purify the resulting dimethyl 2-amino-4,6-dimethyl-3-oxo-3H-phenoxazinone1,9-dicarboxylate.67-68 This structure was confirmed by LCMS (Figure 2.2.1 (b))
Determination of Methyl Actinocin pKa
Twenty-two 0.05M phosphate buffers were made and the pH of each was adjusted
to be roughly half a unit apart spanning the range pH 1-11.5. A 0.05 M methyl actinocin
solution in methanol was also made. Eighty µL of methyl actinocin solution was added to
920 µL of each phosphate buffer in a 10.00 mm quartz cuvette.
We, then, measured each of our cuvette mixtures at the pH’s listed in Figure 2.3.3
and noted the absorbance. This was plotted and fit to a polynomial trend line regression
with the goal of determining the inflection points of these curves. The inflection point is
important because it is the experimental solution to the Henderson-Hasselbach equation at
which pH=pKa.66
Alkylation of Methyl Actinocin
The complete list of reaction conditions is outlined in Figure 2.2.2(a)-(c), however
only one was successful. A deep eutectic solvent (DES) was prepared by mixing 14 mL of
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urea (18.48g, 2 mol, in 14 mL water) with 7 mL choline chloride (7.63g, 1 mol, in 7 mL
water); this mixture was heated to 74oC until the solution became clear.69 Once the solution
was cooled to room temperature, 9 mL of it was added to a 50 mL round bottom flask along
with 1.94x10-5 mol methyl actinocin (dissolved in 1 mL methanol) and 1.56x10-5 mol (1.64
µL) of 1-chlorobutane. The mixture was heated to 50oC overnight. Organics were extracted
from water with ethyl acetate; this organic layer was dried with sodium sulfate and
concentrated in vacuo. Success of the reaction was confirmed by LC/MS (Figure 2.3.2).
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Figure 2.2.1(a)-Synthesis Scheme for Methyl Actinocin
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Figure 2.2.1(b)-LC/MS Trace of Methyl Actinocin
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Figure 2.2.2-Attempted Methyl Actinocin Alkylation Conditions
(a)

Approx. 58 mg (1.63x10-4 mol) was dissolved in 15 mL methanol. Three mL of that
mixture was added to 5 mL water, 5 mL acetonitrile, 250 µL triethyl amine, and 1 mL 1chlorobutane. The mixture was heated to 60oC overnight. Organics were extracted with
methanol and dried with sodium sulfate before being concentrated in vacuo. The resulting
residue was subjected to LC/MS; no reaction observed.
(b)

Approx. 10x acetyl chloride was added slowly to ~50 mg methyl actinocin dissolved in 10
mL anhydrous dichloromethane with 10x trimethylamine also added. The reaction was
stirred at room temperature for 30 min. The reaction mixture was extracted with ethyl
acetate and water. The organic layer was dried with sodium sulfate and concentrated in
vacuo. The resulting residue was subjected to LC/MS; no reaction observed.
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(c)

A deep eutectic solvent (DES) was prepared by mixing 14 mL of urea (18.48g, 2 mol, in
14 mL water) with 7 mL choline chloride (7.63g, 1 mol, in 7 mL water); this mixture was
heated to 74oC until the solution became clear.69 Once the solution was cooled to room
temperature, 9 mL of it was added to a 50 mL round bottom flask along with 1.94x10-5 mol
methyl actinocin (dissolved in 1 mL methanol) and 1.56x10-5 mol (1.64 µL) of 1chlorobutane. The mixture was heated to 50oC overnight. Organics were extracted from
water with ethyl acetate; this organic layer was dried with sodium sulfate and concentrated
in vacuo. Success of the reaction was confirmed by LC/MS
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2.3 Results and Discussion
Synthesis of Methyl Actinocin and pKa Determination
The final product, dubbed “methyl actinocin”, was to have the exact same aromatic
core without the complication of the depsipeptide rings; these were simply approximated
with a methyl group that also served as a way to isolate the phenoxazinone-core aniline as
the only pH sensitive group in our model system.
We, then, determined the wavelength at which the model would show the greatest
variance in UV absorption across the pH range tested. The UV absorption was scanned at
all wavelengths for pH = 1, 1.5, 5.5, 6, 10.5, and 11 (Figure 2.3.1 and Figure 2.3.2). From
this analysis, we determined that 340 nm was the best wavelength to measure changes in
absorbance. To our surprise, when we measured the absorbance of the methyl actinocin in
the various phosphate buffers at 340 nm, two inflection points were revealed, implying that
this position could donate two protons. Furthermore, solving for the trend line equations
generated from the curves in Figure 2.3.3 yields the pKa values 2.976 and 8.429, indicating
that above pH 8.5, the 2-NH2 group of methyl actinocin carries a negative charge and is
likely to be very nucleophilic.
Foreshadowing information that will be presented in Chapter 3, we, also, find it
extremely significant that the largest shifts in UV absorbance that correspond to reactivity
at the 2-NH2 position of methyl actinocin occur between 300-350 nm. It is likely that such
UV shifts also occur in actinomycins that have undergone a chemical reaction at this
position.
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Alkylation of Methyl Actinocin
Having determined that the 2-NH2 methyl actinocin is reactive, we tried several
reaction conditions attempting to alkylate that position. The goal was to attempt to recreate
the type of intramolecular alkylation that would have to occur in β-ring heterocycle
containing actinomycins if the structural motif were formed via this SN2 mechanism.
However, only the reaction utilizing the DES was successful in producing the alkylated
product (Figure 2.3.4). This could indicate that the 2-NH2 group is more sterically hindered
than previously believed. It’s also likely the 1-chlorobutane would not be as strong of an
electrophile in our model as the 1-chlorothreonine being attacked in actinomycins.69-70
Therefore, though the DES is designed to make amines more reactive, we remain
comfortable extrapolating the success of this alkylation to postulate the circumstances
under which an actinomycin would behave similarly.
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Figure 2.3.1- Total Wavelength Chromatogram of Methyl Actinocin at Multiple pH
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Methyl actinocin scanned over wavelengths 200 – 500 nm at two pH’s < 2.976, 2.976 < pH < 8.249, and pH > 8.249.

Figure 2.3.2-Total Wavelength Chromatogram of Methyl Actinocin Zoomed In
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Figure 2.3.1 zoomed in to highlight the shift in UV absorption between 300 – 350 nm when methyl actinocin is a buffer pH
> 8.429.

Figure 2.3.3-Determination of Acid Dissociation Constants for Methyl Actinocin

Determination of the acid dissociation constant (pKa) for methyl actinocin. pKa values
were calculated by solving for ‘X’ in the second derivative equations calculated from the
trend line in each graph. Phosphate buffers made at pH’s 1.05, 1.53, 1.94, 2.52, 3.09, 3.58,
3.97, 4.55, 5.00, 5.51, 5.89, 6.48, 6.94, 7.48, 7.97, 8.59, 8.65, 9.35, 9.85, 9.93, 10.92, and
11.45. The effects on methyl actinocin were measured in triplicate. Averages and standard
deviations shown near inflection points.
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Figure 2.3.4-LC/MS Trace of Successfully Alkylated Methyl Actinocin
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Reaction scheme and LC/MS trace for reaction described in Figure 2.2.2(c). Doubly alkylated product observed at 10.042 min
using DES.

Chapter 3: Comparative Genomic Analysis of Actinomycin G, Y, and Z Gene
Clusters
3.1 Introduction
Although the gene clusters for various other actinomycins have been sequenced and
annotated, the gene cluster producing the actinomycin Y family of compounds in
Streptomyces GÖ-GS12 had not yet been characterized. We felt this was necessary to test
our hypothesis that the unique β-ring heterocycle observed in actinomycin Y5 could be
synthesized through enzymatic means.
We also found it odd that no actinomycin containing a β-ring heterocycle was
observed in the actinomycin Z family considering the family contained nearly all of the
same structural components of the actinomycin Y family including the 4-chlorothreonine
moiety. This disparity between family members could help identify the gene responsible
for the heterocycle formation; if the process was a result of enzymatic transformation, then
it is possible there would be an obvious difference between the gene clusters if the two
were aligned. This required us to sequence the genome of the producing strain of the
actinomycin Z family—Streptomyces fradiae ETH 20675—as the gene cluster responsible
for producing these compounds was also not reported.
We also chose this opportunity of working with these two strains to characterize
the actinomycins produced by each ourselves. The goals of this endeavor were twofold: (1)
to accumulate enough actinomycins containing a β-ring heterocycle to confirm or disprove
its reported unique activity and (2) to identify any novel actinomycin structures, if there
are any that were missed in previous isolations.
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3.2 Methods
Semi-prep HPLC performed Waters 600 controller equipped with a Waters 600 photodiode
array detector, a Waters 2487 dual absorbance detector, and a Grace Apollo C18 (250mm
X 4.5 mm, 5µm) column. Isolation gradient used was as follows: a gradient of 100:0 water:
acetonitrile was increased to 0:100 water acetonitrile over the course of 30 min. This ratio
was maintained for 5 min before returning to 100:0 water: acetonitrile over the course of 1
min. This ratio was maintained for the next 3 min. An AB SCIEX Triple TOF 5600
equipped with a Phenomenex Gemini C18 (100 X 3 mm, 110 Å) column was used to
determine the HRMS of the actinomycin Y family members and a Agilent 6230 TOF
LC/MS equipped with a Phenomenex Gemini C18 (100 X 3 mm, 110 Å) column was used
to determine the HRMS of the actinomycin Z family members. LC/MS gradient is as
follows: 0.4 mL/min flow rate beginning with a ratio of 95:5 water: acetonitrile, increasing
to 0:100 water: acetonitrile over 16 min. This ratio was held for four minutes before
reverting to a 95:5 water: acetonitrile ratio over the next minute. This ratio was held for the
remaining four minutes. A 400 MHz Varian Inova NMR was used to fully elucidate the
structures of the actinomycin Y family members.
Isolation of Streptomyces GÖ-GS12 and Streptomyces fradiae ETH 20675 genomic
DNA
The genomic DNA of Streptomyces GÖ-GS12 and Streptomyces fradiae ETH
20675 was isolated by doing the following: cells were grown in 150 mL of GYM media
(glucose, yeast extract, malt extract) for seven days until sufficient colonies were present.
Colonies were collected by gravity filtration through an open weave cloth. Colonies were
resuspended in 5 mL of SET buffer (75 mM NaCl, 25 mM EDTA at pH 8, 20 mM Tris-
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HCl at pH 7.5) in a 50 mL falcon tube and incubated for 1 hr at 37oC with 100 µL of 50
mg/mL lysozyme solution. Then, 140µL of 20 mg/mL protinase K solution and 600 µL of
10% SDS solution were added to the mixture and mixed by inversion. Afterwards, the
mixture was incubated for 2 hrs at 55oC, occasionally mixing by inversion. Following the
incubation, 2 mL of 5M NaCl was added to the solution and mixed by inversion. The
solution was placed in a 37oC water bath to cool it to 37oC. Once at the correct temperature,
5 mL chloroform was added and mixed by inversion for 30 min at room temperature. The
solution was, then, centrifuged for 15 min at 4000 rpm. The supernatant was transferred to
a fresh tube and 0.6 vol isopropanol was added and mixed by inversion. After ~3 min, DNA
was spooled out of the tube using a glass rod and washed with 70% ethanol. The genomic
DNA was dried under nitrogen gas and redissolved in TE Buffer (25 mM Tris-HCL, pH 8,
25 mM EDTA, pH 8, 0.3M sucrose).71
Sequencing of the Genomic DNA, Gene Cluster Assignment, and Cluster Alignment
The DNA was sequenced using Sanger sequencing and sorted into contigs. We
searched the gene sequence of each contig with the known gene sequence of acmG2’, a
gene encoding a large NRPS, to determine which sequences might contain portions of our
cluster of interest. Additional cosmids were then aligned with the one found to contain the
actinomycin core biosynthesis gene to determine the contiguous gene sequence between
cosmids that likely contained the actinomycin gene clusters. Using FRAMEPLOT—which
takes advantage of the fact Streptomyces sp. overwhelmingly contain a guanine or cytosine
in the wobble position of a translatable gene—we were able to determine the likely open
reading frames that yielded the functional gene. These open reading frames were subjected
to BLAST comparison to determine their putative function (Figure 3.3.1(a)-(c) and Table
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3.3.1). The actinomycin Y and Z gene clusters were then aligned based on similarities
between their primary sequences using the computer program ‘Geneious’.
Isolation of Actinomycin Y and Z family members
The general growth and isolation procedure for the isolation of actinomycins from
Streptomyces GÖ-GS12 are as follows: A seed culture of 150 mL of oatmeal medium
(Quaker Oats ground with mortar and pestle and sterilized by autoclave in Milli-Q water)
in an Erlenmeyer flask was grown for five days at 28oC shaking at 225 rpm until a slight
orange color change was observed. Afterwards, 100 µL of seed culture was added to 150
mL of oatmeal medium spread across several Erlenmeyer flasks (totaling 5 L of oatmeal
media) with an emphasis on adding at least one visible Streptomyces colony to each flask.
These flasks were grown for ~10 days at 28oC shaking at 225 rpm until the media became
a dark orange/red color. After such time, the flasks were emptied and subjected to gravity
filtration to separate the cell pellet from the supernatant.
Acetone was added to the cell pellet to lyse and extract metabolites of interest. This
mixture was stirred at room temperature for 24-48 hours followed by a second gravity
filtration to remove the lysed cellular debris. The acetone fraction was then concentrated
in vacuo to yield a large amount of red solid.
Dichloromethane was added to the supernatant; this mixture was left to stir at room
temperature for 24-48 hours to extract metabolites of interest. The dichloromethane layer
was extracted via separatory funnel and concentrated in vacuo.
The supernatant and pellet extractions were combined by the dissolution of each
solute in as little methanol as possible. This mixture was subjected to a silica column using
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the following solvent system: 1.5 column length of 100% CHCl3, 1.5 column length of
3:97 MeOH:CHCl3, elute with 7:93 MeOH:CHCl3 until yellow/orange color subsides.
Colored fractions were combined and concentrated in vacuo. Solute was redissolved, again,
in as little methanol as possible and added slowly to a gravity filtration column containing
LH-20 sephadex. Orange/ yellow compounds that eluted at the front end of the separation
(indicating they were the largest of the molecules in the concentrated solute mixture) were
collected into fractions of 50 mL falcon tubes. Each tube was analyzed by semi-preparative
HPLC for UV maxima at 240 and 440 nm, indicating a compound that was likely an
actinomycin. Fractions containing these UV maxima were concentrated and the complex
mixture was separated by semi-preparative HPLC utilizing the following gradient. HRMS
and NMR were used to determine the identities of pure peaks, if possible.
3.3 Results and Discussion
Gene Annotation and Alignment of Actinomycin Y and Z clusters
Using BLAST, we were able to annotate both the actinomycin Y and actinomycin
Z gene clusters (Table 3.3.1 and Table 3.3.2). These clusters were, then, aligned by
primary sequence similarity. Our analysis is displayed in Figure 3.3.1. Though we can not
rule out the possibility of a point mutation to an enzyme within the cluster or the interaction
with an enzyme outside of the cluster, there are no obvious differences between the two
clusters such that we would expect the inclusion of actinomycins Y3, Y4, Y5, and Y6 in the
actinomycin Y family and not find similar members of the actinomycin Z family.
Therefore, we hypothesized that there are likely undiscovered actinomycin Z family
members that resembled those in the actinomycin Y family. Specifically, we expected that
if we attempted to isolate actinomycins from Streptomyces fradiae ETH-20675, we would
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find actinomycin Z family members resembling those of the actinomycin Y family
previously listed.
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Table 3.3.1-Gene Annotations for Actinomycin Y Gene Cluster
Gene

Approx. BP Range Within Contig Approx. Size of Gene in BP

Proposed Function

% Identity to Closest Reported Homologue
95% Strep. sclerotialus

Y1

6109-5666

444

Deaminase/Reductase

Y2

7427-6405

1023

Oleoyl-ACP hydrolase

52% Strep. albus

Y3

8007-7489

519

Hypothetical Protein

94% Strep. flavovaribilis , 91% Strep. iak yrus

Y4

8058-8918

861

2,3-Tryptophan dioxygenase

Y5

9876-9439

438

O-methyltransferase

97% Strep. flavovaribilis
94% Strep. flavovaribilis , 92% Strep. iak yrus
96% Strep. flavovaribilis , 94% Strep. iak yrus

Y6

10757-10089

669

LbmU-like protein

Y7

12095-11280

816

Siderophore interacting domain

91% Strep. flavovaribilis

Y8

25039-12305

12735

ACMSIII

94% Strep. flavovaribilis , 90% Strep. iak yrus
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Y9

32790-25039

7752

ACMSII

92% Strep. flavovaribilis , 87% Strep. iak yrus

Y10

34547-33849

699

Long chanin fatty acid-CoA ligase

94% Strep. iak yrus

Y11

34837-34433

405

4-MHA carrier

94% Strep. iak yrus

Y12

36079-35291

789

ABC-type multidrug transporter

97% Strep. flavovaribilis , 92% Strep. iak yrus

Y13

37702-37241

462

TetR transcriptional regulator

96% Strep. flavovaribilis , 92% Strep. iak yrus

Y14

38912-37755

1158

Bifunctional phosphoglucose/phosphomanose isomerase

96% Strep. iak yrus

Y15

39649-38906

744

SDR_c superfamily, oxoreductase, dehydrogenase

96% Strep. iak yrus

Y16

40909-39713

1197

CypC cytochrome P450

94% Strep. iak yrus

Y17

42064-41048

1017

Non-heme alpha-ketogluterate halogenase

97% Strep. flavovaribilis , 95% Strep. iak yrus

Y18

42000-50300

Y19

8301

ACMS II

90% Strep. iak yrus

~12kb (between contigs)

ACMSIII

93% Strep. flavovaribilis , 91% Strep. iak yrus

Y20

3187-2347

840

Aryl hydrolase

88% Strep. flavovaribilis , 92% Strep. iak yrus

Y21

4563-3297

1266

Kynureninase

99% Strep. flavovaribilis , 93% Strep. iak yrus

Y22

5707-4550

1158

Na/H antiporter

92% Strep. iak yrus

Y23

5949-6191

243

MbtH Protein

99% Strep. iak yrus

Y24

6203-6754

552

Hypothetical Protein

93% Strep. flavovaribilis

Y25

7400-6888

512

Hypothetical Protein

96% Strep. flavovaribilis , 94% Strep. iak yrus

Cyp450

96% Strep. flavovaribilis

Y26

Location of each gene, its proposed enzymatic product, and its closest homologues. Gene found on Contig 00116; Gene
found on Contig 00117. We attempted to construct a similar table for the actinomycin Z but the top BLAST search result
was consistently from the actinomycin G cluster with no proposed function.

Figure 3.3.1(a)-Partial Sequence Alignment of Actinomycin Y and Z Gene Clusters

Partial sequence alignment of actinomycin Y and actinomycin Z gene clusters with
statistics highlighting their similarities.
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Figure 3.3.1(b)- Partial Sequence Alignment of Actinomycin Y and Z Gene Clusters

Partial sequence alignment of actinomycin Y and actinomycin Z gene clusters with
statistics highlighting their similarities.
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Figure 3.3.1(c)- Partial Sequence Alignment of Actinomycin Y and Z Gene Clusters

Partial sequence alignment of actinomycin Y and actinomycin Z gene clusters with
statistics highlighting their similarities.
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Isolation and Characterization of Novel Actinomycin Y Family Members
We were able to isolate four new actinomycin Y-family members. Of particular
interest to us during the isolation of actinomycins from Streptomyces GÖ-GS12 were
compounds that contained UV maxima at 240nm, 440nm and a small but noticeable UV
absorption spike ~308nm because no previous actinomycin had been reported with
noteworthy UV absorption in that range of light. We felt that this change in absorption
could indicate the formation of novel motif within the actinomycins. The previously
discovered actinomycin Zp was also isolated for the first time Streptomyces GÖ-GS12.37
The structures of these compounds are listed in Figure 3.3.2.
The most interesting actinomycin discovered was named actinomycin Y6, which
contains both a rearranged β-ring and a β-ring heterocycle. The presence of the β-ring
heterocycle means there is something bound to the 2-NH2 position of the phenoxazinone
core, not unlike what was tested in Chapter 2. Similar to what we observed when we
determined methyl actinocin was in a charged state, actinomycin Y6 has a UV spike at
~308nm. This supports our hypothesis that binding at the 2-NH2 position of the
phenoxazinone-core creates a new UV maximum between 300-340 nm. Y6 also represents
a mechanistic oddity; because the rearranged core is made via two-fold acyl shift and such
a mechanism removes the electrophile in the proposed SN2 attack to create the β-ring
heterocycle, what is the 2-NH2 phenoxazinone group attacking on Y3 to create Y6?72 In
Figure 3.3.3, we outline a possible mechanism for this to occur wherein the protruding
hydroxyl group is eliminated to form an α,β-unsaturated amide with the depsipeptide ring
followed by a Michael-like addition to β-position of the unsaturated amide yielding Y6.
Nucleophiles that attack via Michael addition tend to be “softer”; it would certainly follow
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chemical logic to suggest that the actinomycin core aniline would be tied electronically to
the three-ring aromatic system, spreading out the group’s electronic density, thereby
making the group “softer” than a typical aniline group.73
While Y6 appears to be a hybrid structure of Y3 and Y5, the three compounds take
different shapes when bound to DNA (Figure 3.3.4). Using actinomycin D as the standard
shape for the binding to DNA of these molecules, it is clear that a rearrangement to the
actinomycin core takes the β-ring out of the plane of proper for DNA binding (shown in
yellow, representing Y3). However, if this rearranged core undergoes intramolecular
cyclization to create the β-ring heterocycle (shown in green, representing Y6), the β-ring is
brought back into the correct plane for DNA binding, but position of the α- and β-rings is
greatly different from actinomycin D, appearing to form a more compact shape. This shape
is further compacted if the β-ring rearrangement is removed and only the β-ring heterocycle
remains (shown in red, representing Y5). We believe it is possible that this constricted
shape could yield different activity for this molecule as compared to the remaining known
actinomycins.
Among the four new actinomycins discovered was actinomycin Y7, which contains
a 4-hydroxythreonine moiety.37 This molecule was one that we had expected to find during
our isolation of Streptomyces GÖ-GS12 metabolites because a similar molecule were found
in the closely related actininomycin Z family: actinomycin Z1.36 This molecule also
represented something of a “missing link” in the actinomycin Y family: in order to undergo
the two-fold acyl shift that produced actinomycins Y3 and Y4, an actinomycin containing
a 4-hydroxythronine moiety was necessary, though—until now—none had been reported
within this family of actinomycins. We felt confident that, due to the similarities in
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structure, we would find actinomycin Z homologues in the actinomycin Y family and vice
versa, unless there was a difference between the two gene clusters.
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Figure 3.3.237-Structures of Newly Discovered Actinomycin Y Family Members
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Figure 3.3.3- Proposed Two-Fold Acyl Shift Mechanism Responsible for the
Formation of Actinomycins Y3 and Y4
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Proposed mechanism of formation for actinomycins Y3, Y4, and Y6: Shown above is the
β-ring reacting with itself and a generic base, possibly water. This mechanism appears to
be thermodynamically driven.35, 72
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Figure 3.3.4-Guassian Energy Optimization Model of Actinomycins Binding to DNA

The structure of actinomycin D is shown in blue line. Actinomycin Y3 containing a
rearranged β-ring was shown in yellow, Y5 and Y6 containing the additional ring structure
were shown as red and green lines, respectively. Structures were superimposed by
chromophore cores, and the structures of Y3, Y5 and Y6 were established and optimized
using Gaussian program.74
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Isolation and Characterization of Novel Actinomycin Z Family Members
More than five “pure” peaks were isolated from semi-preparative HPLC, two of
which contained the UV spike at ~308 nm of interest. The masses of these peaks—which
also eluted at similar times to that observed for actinomycin Y6—were [M+H+] 1283.62,
and 1335.66 respectively dubbed Z6 and Z7.
While the mass for Z6 (Vial 1; Figure 3.3.5(a)) could be worked into a compound
containing a β-ring heterocycle, Z7 (Vial 7; Figure 3.4.7(a)) could not. However, the UV
absorption suggested something was bound to the phenoxazinone-core aniline (position 2NH2 in Figure 1.1). Recently, it was discovered that actinomycins could react with
pyruvate to create neoactinomycins A and B.2 Though no unique UV absorption was
reported in the discovery of neoactinomycins, through the work previously described in
Chapter 2, there is a noticeable uptick in absorbance in the ~308 nm range when the
actinomycin core is exposed to a pH lower than 2.976 and greater than 8.429, likely
indicating that there is UV shift when the phenoxazinone-core aniline is protonated or
deprotonated. It would, therefore, stand to reason there is a UV absorption shift into this
range when there is something bound to this aniline. Therefore, based on HRMS and UV
absorption, I believe Z7 and contains the same structure as Z3 with the addition of an oxime
group at position 2-NH2 in Figure 1.1. Unfortunately, we do not have enough of this
material to do confirm this hypothesis via NMR.
Additionally, we were able to observe actinomycin Z compounds with likely
rearranged β-rings as members of a mixture of compounds present in a total ion
chromatogram while doing HRMS of isolated peaks from the semi-preparative HPLC done
during purification. Specifically, we believe the major compound found in Vial 3 (dubbed
55

Z8) (Figure 3.4.7(a)-(k)) contains a rearranged β-ring core due to its mass and lack of
bioactivity. Figure 3.4.7(k) even provides some evidence of an actinomycin Y6 homologue
within the actinomycin Z family due to its mass and shift in UV absorbtion. Therefore, we
were correct in our hypothesis that the actiniomycin Z contained a nearly identical set of
members to the actinomycin Y family, several of which were previously undiscovered.
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Figure 3.3.5(a)-Proposed Structure and Physical Properties of Actinomycin Z Family
Member Found in Vial 1
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Chemical Formula: C61H78N12O18
Exact Mass: 1266.56
Molecular Weight: 1267.36
m/z: 1266.56 (100.0%), 1267.56 (66.0%), 1268.56 (21.4%),
1269.57 (4.6%), 1267.55 (4.4%), 1268.56 (3.7%), 1268.56 (2.9%),
1269.56 (2.4%)
Elemental Analysis: C, 57.81; H, 6.20; N, 13.26; O, 22.72

Proposed structure actinomycin Z family member tested as Vial 1 during bioactivity assays
in Chapter 4. Elution time 22.335 min using described HPLC method.
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Figure 3.3.5(b)-Total Ion Chromatogram and Total Wavelength Channel for Vial 1

58
Total Ion Current (TIC) and Total Wavelength Current (TWC) from Agilent 6230 TOF LC/MS. Highlighting mass and UV
profile of metabolite found at 9.920 min using LC/MS gradient and column.

Figure 3.3.5(c)-HRMS of Vial 1 at 9.920 min

Mass spectrum of metabolite found at 9.920 min.
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Figure 3.3.5(d)-UV Profile of Vial 1 Peak at 9.920 min

UV spectrum of metabolite found at 9.920 min.
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Figure 3.3.5(e)- Total Ion Chromatogram and Total Wavelength Channel for Vial 1

61
Total Ion Current (TIC) and Total Wavelength Current (TWC) from Agilent 6230 TOF LC/MS. Highlighting mass and UV
profile of metabolite found at 13.307 min using LC/MS gradient and column.

Figure 3.3.5(f)- HRMS of Vial 1 at 13.337 min

Mass spectrum of metabolite found at 13.307 min.
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Figure 3.3.5(g)- UV Profile of Vial 1 Peak at 13.337 min

UV spectrum of metabolite found at 13.307 min.
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Figure 3.3.6(a)- Proposed Structure and Physical Properties of Actinomycin Z Family
Member Found in Vial 2
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Chemical Formula: C62H82N12O18
Exact Mass: 1282.59
Molecular Weight: 1283.40
m/z: 1282.59 (100.0%), 1283.59 (67.1%), 1284.59 (22.1%), 1283.58
(4.4%), 1285.60 (4.0%), 1284.59 (3.7%), 1284.59 (3.0%), 1285.59
(2.5%)
Elemental Analysis: C, 58.02; H, 6.44; N, 13.10; O, 22.44

Proposed structure actinomycin Z family member tested as Vial 2 during bioactivity assays
in Chapter 4. Elution time 25.251 min using described HPLC method.

64

Figure 3.3.6(b)- Total Ion Chromatogram and Total Wavelength Channel for Vial 2

65
Total Ion Current (TIC) and Total Wavelength Current (TWC) from Agilent 6230 TOF LC/MS. Highlighting mass and UV
profile of metabolite found at 9.967 min using LC/MS gradient and column.

Figure 3.3.6(c)- HRMS of Vial 2 at 9.967 min

Mass spectrum of metabolite found at 9.967 min.
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Figure 3.3.6(d)- UV Profile of Vial 2 Peak at 9.967 min

UV spectrum of metabolite found at 9.967 min.
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Figure 3.3.7(a)- Proposed Structure and Physical Properties of Actinomycin Z Family
Member Found in Vial 3
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Chemical Formula: C62H84N12O19
Exact Mass: 1300.60
Molecular Weight: 1301.42
m/z: 1300.60 (100.0%), 1301.60 (67.1%), 1302.60 (22.1%), 1301.59 (4.4%), 1303.61 (4.0%), 1302.60 (3.9%),
1302.60 (3.0%), 1303.61 (2.6%)
Elemental Analysis: C, 57.22; H, 6.51; N, 12.92; O, 23.36

Proposed structure actinomycin Z family member tested as Vial 3 during bioactivity assays
in Chapter 4. Elution time 25.251 min using described HPLC method.
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Figure 3.3.7(b)- Total Ion Chromatogram and Total Wavelength Channel for Vial 3

69
Total Ion Current (TIC) and Total Wavelength Current (TWC) from Agilent 6230 TOF LC/MS. Highlighting mass and UV
profile of metabolite found at 11.537 min using LC/MS gradient and column.

Figure 3.3.7(c)- HRMS of Vial 3 at 11.537 min

Mass spectrum of metabolite found at 11.537 min.
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Figure 3.4.3(d)- UV Profile of Vial 3 Peak at 11.537 min

UV spectrum of metabolite found at 11.537 min.
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Figure 3.3.7(e)- Total Ion Chromatogram and Total Wavelength Channel for Vial 3

72
Total Ion Current (TIC) and Total Wavelength Current (TWC) from Agilent 6230 TOF LC/MS. Highlighting mass and UV
profile of metabolite found at 12.097 min using LC/MS gradient and column.

Figure 3.3.7(f)- HRMS of Vial 3 at 12.097 min

Mass spectrum of metabolite found at 12.097 min.
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Figure 3.3.7(g)- UV Profile of Vial 3 Peak at 12.097 min

UV spectrum of metabolite found at 12.097 min.
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Figure 3.3.7(h)- Total Ion Chromatogram and Total Wavelength Channel for Vial 3

75
Total Ion Current (TIC) and Total Wavelength Current (TWC) from Agilent 6230 TOF LC/MS. Highlighting mass and UV
profile of metabolite found at 13.377 min using LC/MS gradient and column.

Figure 3.3.7(i)- HRMS of Vial 3 at 13.377 min

Mass spectrum of metabolite found at 13.377min.
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Figure 3.3.7(j)- UV Profile of Vial 3 Peak at 13.377 min

UV spectrum of metabolite found at 13.377 min.
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Figure 3.3.7(k)- UV Profile of Vial 3 Peak at 13.377 min Zoomed In

78
UV spectrum of metabolite found at 11.537 min zoomed in to reveal new UV maximum between 300-340 nm.

Figure 3.3.8(a)- Proposed Structure and Physical Properties of Actinomycin Z Family
Member Found in Vial 4
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Chemical Formula: C62H84N12O19
Exact Mass: 1300.60
Molecular Weight: 1301.42
m/z: 1300.60 (100.0%), 1301.60 (67.1%), 1302.60 (22.1%), 1301.59
(4.4%), 1303.61 (4.0%), 1302.60 (3.9%), 1302.60 (3.0%), 1303.61
(2.6%)
Elemental Analysis: C, 57.22; H, 6.51; N, 12.92; O, 23.36

Proposed structure actinomycin Z family member tested as Vial 4 during bioactivity assays
in Chapter 4. Elution time 26.518 min using described HPLC method.
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Figure 3.3.8(b)- Total Ion Chromatogram and Total Wavelength Channel for Vial 4

80
Total Ion Current (TIC) and Total Wavelength Current (TWC) from Agilent 6230 TOF LC/MS. Highlighting mass and UV
profile of metabolite found at 10.041 min using LC/MS gradient and column.

Figure 3.3.8(c)- HRMS of Vial 4 at 10.041 min

Mass spectrum of metabolite found at 10.041 min.
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Figure 3.3.8(d)- UV Profile of Vial 4 Peak at 10.041 min

UV spectrum of metabolite found at 10.041 min.
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Figure 3.3.8(e)- Total Ion Chromatogram and Total Wavelength Channel for Vial 4

83
Total Ion Current (TIC) and Total Wavelength Current (TWC) from Agilent 6230 TOF LC/MS. Highlighting mass and UV
profile of metabolite found at 11.614 min using LC/MS gradient and column.

Figure 3.3.8(f)- HRMS of Vial 4 at 11.614 min

Mass spectrum of metabolite found at 11.614 min.
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Figure 3.3.8(g)- UV Profile of Vial 4 Peak at 11.614 min

UV spectrum of metabolite found at 11.614 min.
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Figure 3.3.8(h)- Total Ion Chromatogram and Total Wavelength Channel for Vial 4

86
Total Ion Current (TIC) and Total Wavelength Current (TWC) from Agilent 6230 TOF LC/MS. Highlighting mass and UV
profile of metabolite found at 12.100 min using LC/MS gradient and column.

Figure 3.3.8(i)- HRMS of Vial 4 at 12.100 min

Mass spectrum of metabolite found at 12.100 min.
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Figure 3.3.8(j)- UV Profile of Vial 4 Peak at 12.100 min

UV spectrum of metabolite found at 12.100 min.
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Figure 3.3.8(k)- Total Ion Chromatogram and Total Wavelength Channel for Vial 4

89
Total Ion Current (TIC) and Total Wavelength Current (TWC) from Agilent 6230 TOF LC/MS. Highlighting mass and UV
profile of metabolite found at 14.094 min using LC/MS gradient and column.

Figure 3.3.8(l)- HRMS of Vial 4 at 14.094 min

Mass spectrum of metabolite found at 14.094 min.
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Figure 3.3.8(m)- UV Profile of Vial 4 Peak at 14.094 min

UV spectrum of metabolite found at 14.094 min.
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Figure 3.3.9(a)- Proposed Structure and Physical Properties of Actinomycin Z Family
Member Found in Vial 5
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Chemical Formula: C62H84N12O17
Exact Mass: 1268.61
Molecular Weight: 1269.42
m/z: 1268.61 (100.0%), 1269.61 (67.1%), 1270.61 (22.1%), 1269.60
(4.4%), 1271.62 (4.0%), 1270.61 (3.5%), 1270.61 (3.0%), 1271.62
(2.3%)
Elemental Analysis: C, 58.66; H, 6.67; N, 13.24; O, 21.43

Proposed structure actinomycin Z family member tested as Vial 5 during bioactivity assays
in Chapter 4. Elution time 30.099 min using described HPLC method.

92

Figure 3.3.9(b)- Total Ion Chromatogram and Total Wavelength Channel for Vial 5

93
Total Ion Current (TIC) and Total Wavelength Current (TWC) from Agilent 6230 TOF LC/MS. Highlighting mass and UV
profile of metabolite found at 10.043 min using LC/MS gradient and column

Figure 3.3.9(c)- HRMS of Vial 5 at 10.043 min

Mass spectrum of metabolite found at 10.043 min.
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Figure 3.3.9(d)- UV Profile of Vial 5 Peak at 10.043 min

UV spectrum of metabolite found at 10.043 min.
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Figure 3.3.9(e)- UV Profile of Vial 5 Peak at 10.043 min Zoomed In

96
UV spectrum of metabolite found at 10.043 min zoomed in to reveal new UV maximum between 300-340 nm.

Figure 3.3.9(f)- Total Ion Chromatogram and Total Wavelength Channel for Vial 5

97
Total Ion Current (TIC) and Total Wavelength Current (TWC) from Agilent 6230 TOF LC/MS. Highlighting mass and UV
profile of metabolite found at 13.696 min using LC/MS gradient and column.

Figure 3.3.9(g)- HRMS of Vial 5 at 13.696 min

Mass spectrum of metabolite found at 13.696 min.
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Figure 3.3.9(h)- UV Profile of Vial 5 Peak at 13.696 min

UV spectrum of metabolite found at 13.696 min.
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Figure 3.3.9(i)- Total Ion Chromatogram and Total Wavelength Channel for Vial 5

100
Total Ion Current (TIC) and Total Wavelength Current (TWC) from Agilent 6230 TOF LC/MS. Highlighting mass and UV
profile of metabolite found at 14.736 min using LC/MS gradient and column.

Figure 3.3.9(j)- HRMS of Vial 5 at 14.736 min

Mass spectrum of metabolite found at 14.736 min.

101

Figure 3.3.9(k)- UV Profile of Vial 5 Peak at 14.736 min

UV spectrum of metabolite found at 14.736 min.
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Figure 3.3.9(l)- UV Profile of Vial 5 Peak at 14.736 min Zoomed In

103
UV spectrum of metabolite found at 14.736 min zoomed in to reveal new UV maximum between 300-340 nm.

Figure 3.3.9(m)- Total Ion Chromatogram and Total Wavelength Channel for Vial 5

104
Total Ion Current (TIC) and Total Wavelength Current (TWC) from Agilent 6230 TOF LC/MS. Highlighting mass and UV
profile of metabolite found at 15.989 min using LC/MS gradient and column.

Figure 3.3.9(n)- HRMS of Vial 5 at 15.898 min

Mass spectrum of metabolite found at 15.898 min.
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Figure 3.3.9(o)- UV Profile of Vial 5 Peak at 15.898 min

UV spectrum of metabolite found at 15.898 min.
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Figure 3.3.9(p)- Total Ion Chromatogram and Total Wavelength Channel for Vial 5

107
Total Ion Current (TIC) and Total Wavelength Current (TWC) from Agilent 6230 TOF LC/MS. Highlighting mass and UV
profile of metabolite found at 16.500 min using LC/MS gradient and column.

Figure 3.4.5(q)- HRMS of Vial 5 at 16.500 min

Mass spectrum of metabolite found at 16.500 min.
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Figure 3.3.9(r)- UV Profile of Vial 5 Peak at 16.500 min

UV spectrum of metabolite found at 16.500 min.
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Figure 3.3.10(a)- Proposed Structure and Physical Properties of Actinomycin Z
Family Member Found in Vial 6
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Chemical Formula: C62H83ClN12O17
Exact Mass: 1302.57
Molecular Weight: 1303.86
m/z: 1302.57 (100.0%), 1303.57 (67.1%), 1304.57 (32.0%), 1304.58
(22.1%), 1305.57 (21.4%), 1306.57 (7.1%), 1305.58 (4.8%), 1303.57
(4.1%), 1304.57 (3.5%), 1304.57 (3.0%), 1305.58 (2.3%), 1305.56
(1.4%), 1307.58 (1.3%), 1306.57 (1.1%)
Elemental Analysis: C, 57.11; H, 6.42; Cl, 2.72; N, 12.89; O, 20.86

Proposed structure actinomycin Z family member tested as Vial 6 during bioactivity assays
in Chapter 4. Elution time 30.779 min using described HPLC method.
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Figure 3.3.10(b)- Total Ion Chromatogram and Total Wavelength Channel for Vial 6

111
Total Ion Current (TIC) and Total Wavelength Current (TWC) from Agilent 6230 TOF LC/MS. Highlighting mass and UV
profile of metabolite found at 10.043 min using LC/MS gradient and column.

Figure 3.3.10(c)- HRMS of Vial 6 at 10.043 min

Mass spectrum of metabolite found at 10.043 min.
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Figure 3.3.10(d)- UV Profile of Vial 6 Peak at 10.043 min

UV spectrum of metabolite found at 10.043 min

113

Figure 3.3.10(e)- UV Profile of Vial 6 Peak at 10.043 min Zoomed In

114
UV spectrum of metabolite found at 10.043 min zoomed in to reveal new UV maximum between 300-340 nm.

Figure 3.3.10(f)- Total Ion Chromatogram and Total Wavelength Channel for Vial 6

115
Total Ion Current (TIC) and Total Wavelength Current (TWC) from Agilent 6230 TOF LC/MS. Highlighting mass and profile
of metabolite found at 13.883 min using UV LC/MS gradient and column.

Figure 3.3.10(g)- HRMS of Vial 6 at 13.883 min

Mass spectrum of metabolite found at 13.883 min.
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Figure 3.3.10(h)- UV Profile of Vial 6 Peak at 13.883 min

UV spectrum of metabolite found at 13.883 min.

117

Figure 3.3.10(i)- Total Ion Chromatogram and Total Wavelength Channel for Vial 6

118
Total Ion Current (TIC) and Total Wavelength Current (TWC) from Agilent 6230 TOF LC/MS. Highlighting mass and UV
profile of metabolite found at 16.336 min using LC/MS gradient and column.

Figure 3.3.10(j)- HRMS of Vial 6 at 16.336 min

Mass spectrum of metabolite found at 16.336 min.
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Figure 3.3.10(k)- UV Profile of Vial 6 Peak at 16.336 min

UV spectrum of metabolite found at 16.336min.
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Figure 3.3.11(a)- Proposed Structure and Physical Properties of Actinomycin Z
Family Member Found in Vial 7
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Chemical Formula: C62H83ClN12O19
Exact Mass: 1334.56
Molecular Weight: 1335.86
m/z: 1334.56 (100.0%), 1335.56 (67.1%), 1336.56 (32.0%), 1336.57
(22.1%), 1337.56 (21.4%), 1338.56 (7.1%), 1337.57 (4.8%), 1335.56
(4.4%), 1336.56 (3.9%), 1336.56 (3.0%), 1337.57 (2.6%), 1339.57
(1.5%), 1337.55 (1.4%), 1338.56 (1.2%)
Elemental Analysis: C, 55.75; H, 6.26; Cl, 2.65; N, 12.58; O, 22.76

Proposed structure actinomycin Z family member tested as Vial 7 during bioactivity assays
in Chapter 4. Elution time 24.370 min using described HPLC method.
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Figure 3.3.11(b)- Total Ion Chromatogram and Total Wavelength Channel for Vial 7

122
Total Ion Current (TIC) and Total Wavelength Current (TWC) from Agilent 6230 TOF LC/MS. Highlighting mass and UV
profile of metabolite found at 11.588 min using LC/MS gradient and column.

Figure 3.3.11(c)- HRMS of Vial 7 at 11.588 min

Mass spectrum of metabolite found at 11.588 min.

123

Figure 3.3.11(d)- UV Profile of Vial 7 Peak at 11.588 min

UV spectrum of metabolite found at 11.588 min.
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Figure 3.3.11(e)- Total Ion Chromatogram and Total Wavelength Channel for Vial 7

125
Total Ion Current (TIC) and Total Wavelength Current (TWC) from Agilent 6230 TOF LC/MS. Highlighting mass and UV
profile of metabolite found at 13.401 min using LC/MS gradient and column.

Figure 3.3.11(f)- HRMS of Vial 7 at 13.041 min

Mass spectrum of metabolite found at 13.041 min.
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Figure 3.3.11(g)- UV Profile of Vial 7 Peak at 13.041 min

UV spectrum of metabolite found at 13.041 min.
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Figure 3.3.12(a)- Proposed Structure and Physical Properties of Actinomycin Z
Family Member Found in Vial 8
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Chemical Formula: C61H81ClN12O18
Exact Mass: 1304.55
Molecular Weight: 1305.84
m/z: 1304.55 (100.0%), 1305.55 (66.0%), 1306.55 (32.0%), 1306.55 (21.4%), 1307.55 (21.1%), 1308.55
(6.8%), 1305.55 (4.4%), 1307.56 (3.7%), 1306.55 (3.7%), 1306.55 (2.9%), 1307.56 (2.4%), 1309.56
(1.5%), 1307.54 (1.4%), 1308.55 (1.2%)
Elemental Analysis: C, 56.11; H, 6.25; Cl, 2.71; N, 12.87; O, 22.05

Proposed structure actinomycin Z family member tested as Vial 8 during bioactivity assays
in Chapter 4. Elution time 25.250 min using described HPLC method.
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Figure 3.3.12(b)- Total Ion Chromatogram and Total Wavelength Channel for Vial 8

129
Total Ion Current (TIC) and Total Wavelength Current (TWC) from Agilent 6230 TOF LC/MS. Highlighting mass and UV
profile of metabolite found at 11.782 min using LC/MS gradient and column.

Figure 3.3.12(c)- HRMS of Vial 8 at 11.782 min

Mass spectrum of metabolite found at 11.782 min.

130

Figure 3.3.12(d)- UV Profile of Vial 7 Peak at 11.782 min

UV spectrum of metabolite found at 11.782 min.
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Figure 3.3.12(e)- Total Ion Chromatogram and Total Wavelength Channel for Vial 8

132
Total Ion Current (TIC) and Total Wavelength Current (TWC) from Agilent 6230 TOF LC/MS. Highlighting mass and UV
profile of metabolite found at 12.800 min using LC/MS gradient and column.

Figure 3.3.12(f)- HRMS of Vial 8 at 12.800 min

133
Mass spectrum of metabolite found at 12.800 min.

Figure 3.3.12(g)- UV Profile of Vial 8 Peak at 12.800 min

134
UV spectrum of metabolite found at 12.800 min.

Figure 3.3.12(h)- Total Ion Chromatogram and Total Wavelength Channel for Vial 8

135
Total Ion Current (TIC) and Total Wavelength Current (TWC) from Agilent 6230 TOF LC/MS. Highlighting mass and UV
profile of metabolite found at 13.435 min using LC/MS gradient and column.

Figure 3.3.12(i)- HRMS of Vial 8 at 13.435 min

Mass spectrum of metabolite found at 13.435 min.
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Figure 3.3.12(j)- UV Profile of Vial 8 Peak at 13.435 min

UV spectrum of metabolite found at 13.435 min.
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Figure 3.3.12(k)- Total Ion Chromatogram and Total Wavelength Channel for Vial 8

138
Total Ion Current (TIC) and Total Wavelength Current (TWC) from Agilent 6230 TOF LC/MS. Highlighting mass and UV
profile of metabolite found at 13.600 min using LC/MS gradient and column.

Figure 3.3.12(l)- HRMS of Vial 8 at 13.600 min

Mass spectrum of metabolite found at 13.600 min.
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Figure 3.3.12(m)- UV Profile of Vial 8 Peak at 13.600 min

UV spectrum of metabolite found at 13.600 min.
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Figure 3.3.12(n)- UV Profile of Vial 8 Peak at 13.600 min Zoomed In

141
UV spectrum of metabolite found at 13.600 min zoomed in to reveal new UV maximum between 300-340 nm.

Figure 3.3.13(a)- Proposed Structure and Physical Properties of Actinomycin Z
Family Member Found in Vial 9
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Chemical Formula: C62H84N12O19
Exact Mass: 1300.60
Molecular Weight: 1301.42
m/z: 1300.60 (100.0%), 1301.60 (67.1%), 1302.60 (22.1%),
1301.59 (4.4%), 1303.61 (4.0%), 1302.60 (3.9%), 1302.60
(3.0%), 1303.61 (2.6%)
Elemental Analysis: C, 57.22; H, 6.51; N, 12.92; O, 23.36
Proposed structure actinomycin Z family member tested as Vial 9 during bioactivity assays
in Chapter 4. Elution time 20.521 min using described HPLC method.
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Figure 3.3.13(b)- Total Ion Chromatogram and Total Wavelength Channel for Vial 9

143
Total Ion Current (TIC) and Total Wavelength Current (TWC) from Agilent 6230 TOF LC/MS. Highlighting mass and UV
profile of metabolite found at 9.400 min using LC/MS gradient and column.

Figure 3.3.13(c)- HRMS of Vial 9 at 9.400 min

Mass spectrum of metabolite found at 9.400 min.
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Figure 3.3.13(d)- UV Profile of Vial 9 Peak at 9.400 min

UV spectrum of metabolite found at 9.400 min.
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Figure 3.3.13(e)- Total Ion Chromatogram and Total Wavelength Channel for Vial 9

146
Total Ion Current (TIC) and Total Wavelength Current (TWC) from Agilent 6230 TOF LC/MS. Highlighting mass and UV
profile of metabolite found at 9.764 min using LC/MS gradient and column.

Figure 3.3.13(f)- HRMS of Vial 9 at 9.764 min

Mass spectrum of metabolite found at 9.764 min.
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Figure 3.3.13(g)- UV Profile of Vial 9 Peak at 9.764 min

UV spectrum of metabolite found at 9.764 min.
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Figure 3.3.13(h)- Total Ion Chromatogram and Total Wavelength Channel for Vial 9

149
Total Ion Current (TIC) and Total Wavelength Current (TWC) from Agilent 6230 TOF LC/MS. Highlighting mass and UV
profile of metabolite found at 9.850 min using LC/MS gradient and column.

Figure 3.4.9(i)- HRMS of Vial 9 at 9.850 min

Mass spectrum of metabolite found at 9.850 min.

150

Figure 3.3.13(j)- UV Profile of Vial 9 Peak at 9.850 min

UV spectrum of metabolite found at 9.850 min.

151

Figure 3.4.9(k)- Total Ion Chromatogram and Total Wavelength Channel for Vial 9

152
Total Ion Current (TIC) and Total Wavelength Current (TWC) from Agilent 6230 TOF LC/MS. Highlighting mass and UV
profile of metabolite found at 12.100 min using LC/MS gradient and column.

Figure 3.3.13(l)- HRMS of Vial 9 at 12.100 min

Mass spectrum of metabolite found at 12.100 min.
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Figure 3.3.13(m)- UV Profile of Vial 9 Peak at 12.100 min

UV spectrum of metabolite found at 12.100 min.
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Chapter 4: Analysis of Biological Activity of Newly Isolated Actinomycins and
Instigation of β-Ring Heterocycle Formation
4.1 Introduction
As has been described in Section 1.3, many actinomycin congeners have been
discovered, each with their own small difference. These compounds had their biological
activities compared to actinomycin D in Table 1.3.1, which also compares which
differences to the actinomycin scaffold improve or reduce the biological activity of these
molecules. We decided to perform a similar study of the biological activity of our newly
discovered actinomycins to add to enhance this area of study.
However, the compound that had garnered the most interest for its unique activity—
actinomycin Y5—still eluded us. Because we had such difficulty isolating actinomycin Y5,
we decided to synthesize a model compound that we could make cheaply and abundantly.
We also hoped that the synthesis of such a model would allow us to test various reaction
conditions to attempt to form the β-ring heterocycle that we believe is imperative to the
molecules’ peculiar activity. These reaction conditions would also serve as a barometer for
how “likely” the spontaneous formation of this heterocycle would be, given the power of
the reagents added. We also hoped to use these same reaction conditions to stimulate the
formation of a β-ring heterocycle in 4-chlorothreonine containing actinomycins, such as
actinomycin Z5.
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4.2 Methods
Experiments confirmed by LC/MS in this chapter were done so utilizing an Agilent
Eclipse XDB-C18 10mm column attached to an Agilent Technologies 6120 Quadrupole
LC/MS and an AB SCIEX Triple TOF 5600 equipped with a Phenomenex Gemini C18
(100 X 3 mm, 110 Å) column. The same gradient was used for both: 0.4 mL/min flow rate
beginning with a ratio of 95:5 water: acetonitrile, increasing to 0:100 water: acetonitrile
over 16 min. This ratio was held for four minutes before reverting to a 95:5 water:
acetonitrile ratio over the next minute. This ratio was held for the remaining four minutes.
A 400 MHz Varian Inova NMR was used to fully elucidate the structure of 3-chloro-1propanol ester actinocin.
Determination of actinomycins Y and Z minimum inhibitory concentration (MIC)
The MIC of the newly discovered actinomycin Y6-Y9 and all isolated actinomycin
Z compounds was determined as follows. The bacterial strains Staphylococcus aureus
ATCC 6538, Micrococcus lutens ATCC 15307, Bacillus subtilis ATCC 6633, Salmonella
enterica ATCC 10708, Escherichia coli ATCC 12345 and Mycobacterium aurum ATCC
23366 as well as the fungal strain Saccharomyces cerevisiae ATCC 204508 were selected
as representative strains to assess the antimicrobial activity of these compounds. S. aureus
and M. lutens were grown in tryptic soy broth (BD211825), while B. subtilis and E.coli
were grown in LB medium BD244620), and S. enterica was grown in nutrient broth (BD
234000). Middlebrook 7H9 with OADC enrichment (Sigma Aldrich M0178-500G) was
used to grow M. aurum and YAPD (ATCC medium number 1069) was used to grow S.
cerevisie. These strains were grown individually in 5 mL of their respective mediums for
16 h at 37oC with shaking (250 rpm). A 100 µL aliquot of fully grown culture was diluted
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using the same respective sterile medium to an OD600 ~0.1. Aliquots (160 µL) of each
diluted culture were added to individual wells of a 96-well plate along with 2 µL of serially
diluted test compound. These serial dilutions began from an ~10 µg/mL stock solution and
each was a tenfold dilution of the previous mixture. The range of maximum final
concentrations within each well were maintained to assess antimicrobial activity of these
compounds compared to the negative control vehicle (DMSO) and the ppositive controls
(rifampicin and ciprofloxacin for M. aurum, amphotericin B for S. cerevisiae, and
kanamycin for the remaining microorganisms tested). These culture plates were incubated
at 20-37oC for 16-48 h with shaking (160 rpm). Afterwards, the OD600 values of each well
was measured by FLUOstar Omega scanning microplate spectrophotometer (BMG
Labtech). These OD600 values were normalized to the negative control wells containing no
drug with 100% microorganism viability. The minimum concentration of the tested
compound that prevented microorganism growth was noted as the MIC.37, 75-76
Determination of actinomycins Y and Z cytotoxic potency
These compounds were also tested for their cytotoxicity against PC3 human
prostate cancer cells and A549 human lung non-small-cell carcinoma cells. This was done
using a resazurin-based cytotoxicity assay (or AlamarBlue assay). Cytotoxcity of the tested
compounds is assessed by measuring the reduction of resazurin (7-hydroxy-10oxidophenoazin-10-ium-3-one) to its fluorescent product resorufin. A549 and PC3 cells,
purchased from ATCC (Manassas, VA, USA) were grown in DMEM/F-12 Kaighn’s
modification and MEM/EBSS media (Thermo Scientific Hyclone, Logan, UT, USA),
respectively. To the media, 10% heat-inactivated fetal bovine serum (FBS), 100 U/mL
penicillin, 100 µg/mL streptomycin, and 2mM L-glutamine was added. Cells were seeded
157

at a density of 5 x 103 cells per well onto 96-well culture plates containing a clear bottom
(Corning, NY, USA). These cells were incubated at 37oC for 24 h in a humidified
atmosphere containing 5% CO2. Afterwards, the cells were exposed to the tested
compounds for 2 days (positive controls: 1.5 mM hydrogen peroxide and 10 µg/mL
actinomycin D). After this period of exposure had ended, resazurin (150 µM final
concentration) was added to each well and the plates were shaken for 10 s before another
3 h incubation period at 37oC to allow viable cells to reduce the resazurin to resorufin.
Fluoresence intensity for resorufin was detected by a FLUOstar Omega scanning
microplate spectrofluorometer (BMG LABTECH GmbH, Ortenberg, Germany) using an
excitation wavelength of 560 nm and an emission wavelength of 590 nm. This assay was
replicated three separate times and each replication, the fluorescence emission values of
resorufin in treated cells were normalized to the mean resorufin emission values of the
untreated control cells (100% metabolically active, viable cells).37
Synthesis of 3-chloro-1-propanol ester actinocin; a model for actinomycin Y5
Described in Figure 4.2.1 (a) is the synthesis scheme used to synthesize 3-chloro1-propanol ester actinocin. It is very similar to the procedure used to synthesize methyl
actinocin in Section 2.1. (1) 3-hydroxy-4-methyl nitrobenzoic acid (0.52g) was dissolved
in 15 mL of 3-chloro-1-proanol in a 50 mL round bottom flask. 4 mL of thionyl chloride
was added dropwise with stirring. The mixture was heated to 60oC under a reflux condenser
and left to react overnight. Saturated sodium bicarbonate and ethyl acetate were added to
extract the product, 3-hydroxy-4-methyl-1-3’chloropronaol-nitrobenzoic ester. The
organic layer was separated, dried with sodium sulfate and the excess ethyl acetate was
removed in vacuo. However, we were unable to completely remove the excess 3-chloro-1158

propanol due to its organic solubility and viscous nature leading to a high boiling point.
However, we decided to proceed with the following reaction.
(2) To a clean, dry 50 mL double-necked round bottom flask, a few spatulas of
palladium on activated carbon were added. The flask was then sealed and the air was
removed and replaced by nitrogen gas. 3-hydroxy-4-methyl-1-3’chloropronaolnitrobenzoic ester was dissolved in 20 mL anhydrous methanol and injected into the sealed
flask. Hydrogen gas was then bubbled into the mixture at room temperature. The reaction
was left under hydrogen gas for 48 hours. The palladium on activated carbon was removed
by vacuum filtration through celite. Methanol was removed in vacuo leaving the remaining
3-chloro-1-propanol and the product 3-hydroxy-4-methyl-1-3’chloropronaol-anthranilic
ester
(3) 10 mL of methanol and 10 mL of 0.067M potassium phosphate solution were
added to the remaining solution of 3-hydroxy-4-methyl-1-3’chloropronaol-anthranilic
ester and 3-chloro-1-propanol along with 1.16g of potassium ferricyanide. 1.5 mL of 2M
sodium hydroxide was added to the mixture to readjust the pH into the 7-8 range.67 This
produced an insoluble orange solid, likely an iron complex. The solution was covered in
tin foil and stirred at room temperature under nitrogen balloon overnight. The orange
insoluble flakes were removed by filtration through celite. A PLC silica gel was run (5:1
hexanes:ethyl acetate) to reveal five different spots. These spots were scratched out of the
PLC silica gel and extracted, extracted with ethyl acetate and subjected to LC/MS. It was
revealed that the yellow product (third spot from the top of the gel) was the product. The
remainder of the concentrated reaction mixture was separated by silica column (3:1
hexanes:ethyl acetate). Concentrated orange/yellow fractions were collected and
159

concentrated in vacuo. A small amount of liquid remained in the round bottom flask and
was discarded, assuming it was contaminant. The remaining red solid was washed via
vacuum filtration with pentane, dried. Total yield of all three reaction steps was 11.25%
(68.63 mg).
Reaction conditions to form β-ring heterocycle in 3-chloro-1-propanol ester actinocin
To a 50 mL round bottom flask, 4.24 mL of 10 mM 3-chloro-1-propanol ester
actinocin stock solution (0.0424 mol) was dried and redissolved in 5 mL
dimethylformamide (DMF). To this, 33 mg of cesium carbonate (1.01E-04 mol) and 5.63
mg of sodium iodide (3.77E-05 mol) were added. The mixture was stirred at 60oC under a
reflux condenser overnight.77
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Figure 4.2.1-Synthesis Scheme for 1-Chloro-3-Proponal Actinocin and Underlying
Logic
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4.3 Results and Discussion
Activity of Newly Discovered Actinomycin Y compounds
The results from this MIC assay to determine antibacterial activity are summarized
in Table 4.3.1(a). Once again, actinomycin Y6 yielded the most interesting results when
compared to the activity of actinomycins Y3 and Y4. The muted but measurable activity of
actinomycin Y6 against the gram positive bacteria tested is a substantial improvement over
the immeasurable activities of Y3 and Y4 indicating that the β-ring heterocycle does restore
some of the efficacy lost from the β-ring core rearrangement. This confirmed part of our
hypothesis in Section 3.3 and Figure 3.3.4; the tighter, more compact shape that is near
the correct plane for DNA binding of actinomycin Y6 appears to lead to an improvement
in activity. However, actinomycin Y6 is still several thousand times worse as an antibiotic
when compared to the activity of actinomycin D, a far cry from the less than 10-fold
difference observed in antibacterial activity between actinomycin D and actinomycin Y5
(Tables 1.3 and 4.3.1(c)).35 Actinomycin Y7 also showed considerably poor but measurable
activity against gram positive bacteria. This is consistent with results observed from testing
the antibacterial potentcy of actinomycin Z1.36
Against the cancer cells lines tested (Tables 4.3.1 (b) and (c)), the results were
consistent with previously observed structure-activity trends. Actinomycin Y6 showed
extremely poor activity compared to actinomycin D, though overall showed nanomolar
EC50 against PC3 and A549 cancer cells. Previous cytotoxicity assays done to determine
the GI50 of actinomycin Y family members Y3, Y4, and Y5 all showed immeasurable or
µg/mL quantities required to prevent growth in HM02 gastric adenocarcinoma cells,
HepG2 hepatocellular carcinoma cells, and MCF7 breast adenocarcinoma cells.35 In our
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hands, we were able to determine a measurable EC50 value for Y3 and Y4, which we found
to be over 100 times less potent than Y6 and nearly 100,000 times less potent than
actinomycin D. This drastic change in activity likely means that the cancer cells tested are
particularly susceptible to actinomycin Y6 or that the combination of β-ring core
rearrangement and β-ring heterocycle is much more active against cancer cells than having
either of these structural modifications alone. Again, actinomycin Y7 proved to be just as
ineffective at instigating cell death as previously reported actinomycins containing a β-ring
4-hydroxythronine and actinomycins with fewer proline hydroxylations (i.e. actinomycin
Y9 vs actinomycin Y8) proved to be more active.35-36
Activity of Newly Discovered Actinomycin Z compounds
The minimum inhibitory concentrations (MIC) of the isolated actinomycin Z
compounds were determined according to the same protocol used to determine those of the
actinomycin Y compounds outlined in Section 4.2. However, these compounds were only
tested against the bacterial strains Staphylococcus aureus ATCC 6538 and Escherichia coli
ATCC 12345. The results are summarized in Tables 4.3.2(a) and (b) and are largely similar
to what we observed in the actinomycin Y family. Compounds 6 and 8 containing the 4chlorothreonine moiety (and likely the previously discovered actinomycins Z5 and Z3,
respectively) performed similarly to actinomycin D against the cell types tested. However,
compound 7 (dubbed Z7) likely has both a 4-chlorothreonine moiety but also has an oxime.
While the location of this particular hydroxyl group is interesting, potentially hinting at
another actinomycin that could be a result of the phenoxazinone-core reactivity, it does
seem that having three exposed hydroxyl groups on an actinomycin scaffold reduces the
bioactivity of the molecule 1000-fold. The activity of compounds 3 and 9 supports this
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claim. Compounds 1 and 2 both appear to have β-ring heterocycles as a part of their
structure. However, it is impossible to tell if these compounds are more similar to
actinomycin Y5 with the actinocin core intact or to actinomycin Y6 with a rearranged core
from HRMS data alone. Likewise, it is also impossible to discern if any of the multihydroxylated compounds possess a rearranged core with this being the reason for their lack
of activity, though we believe Vial 3 (dubbed Z8) does when factoring in previously
discovered actinomycins and unique elution time.
Characterization of 3-chloro-1-propanol ester actinocin and β-ring heterocycle
formation
The model compound 3-chloro-1-propanol ester actinocin was successfully
synthesized and characterized (Figures 4.3.1(a)-(e)). We were, then, able to form a β-ring
heterocycle in our model 3-chloro-1-propanol ester actinocin (Figure 4.3.2(a)-(h)). A
sample of the reaction mixture was taken after 17 h and revealed a new peak at ~15.5 min
(Figure 4.3.2(b)). Of note, the UV profile did change between starting material and
product, raising a new UV maximum at ~310nm (Figure 4.3.2(d), (g), and (h)). This would
seem to confirm that the formation of a β-ring heterocycle that attaches to the actinocin
core at the 2-NH2 position causes the shift in UV absorption. We hypothesize that any nonUV active group attached to that position is likely to cause this same shift in absorption.
The reaction conditions present in Figure 4.3.2(a) were repeated without the
inclusion of sodium iodide to test if the halide replacement is required to stimulate the
formation of the β-ring heterocycle. A sample of this reaction mixture was subjected to
LCMS; while the mass of the cyclized product was observed at the correct elution time, its
abundance was incredibly small to the point of it being unlikely the formation of the
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cyclized product would’ve been noticed had we not been looking for it. Reaction conditions
with and without the presence of sodium iodide will be tested for the β-ring heterocycle
formation in the 4-chlorothreonine containing actinomycin Z5. We hypothesize that this
moiety is a better electrophile than the chlorine atom of the 3-chloro-1-propanol ester
actinocin involved in the cyclization.
It is also worth noting that the base used in these reactions, cesium carbonate, has
a pKa of 10.33, which we would consider a mild base. The carbonate ion itself is widely
available in nature and there are several other naturally found basic compounds that could
interact with actinomycins after their assembly to cause this rearrangement. The cesium
counter ion appears to be important to help solubilize the base in DMF as compared to
sodium and potassium carbonate.78
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Table 4.3.1-Activity of Newly Discovered Actinomycin Y Compounds
(a)

(b)

(c)

4.3.1(a) displays calculated MIC values for a variety of Gram-positive, Gram-negative,
and spore forming bacteria; 4.3.1(b) displays calculated IC50 values for PC3 (prostate)
cancer cells and A549 (lung) cancer cells.37 4.3.1(c) displays the ratio of activity of the
newly discovered actinomycins Y6-Y9 to the actinomycin D tested during each respective
MIC or IC50 determinations, as was done for Table 1.3.
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Table 4.3.2- Activity of Isolated Actinomycin Z Compounds
(a)

(b)

4.3.2(a) displays calculated EC50 values for for PC3 (prostate) cancer cells and A549 (lung)
cancer cells; 4.3.2(b) displays the ratio of activity of the isolated actinomycins Z
compounds (denoted as samples 1-9) to the actinomycin D tested during each respective
MIC or IC50 determinations, as was done for Table 1.3. This includes the antibacterial
activity; activity was only observed against S. aureus for all compounds tested.
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Figure 4.3.1(a)- Mass spectrum and Total Ion Chromatogram of 3-chloro-1-propanol ester actinocin
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Figure 4.3.1(b)- 1H NMR of 3-Chloro-1-Propanol Ester Actinocin
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Figure 4.3.1(c)- gCOSY of 3-Chloro-1-Propanol Ester Actinocin
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Figure 4.3.1(d)- gHMBC of 3-Chloro-1-Propanol Ester Actinocin
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Figure 4.3.1(e)- gHSQC superimposed onto gHMBC of 3-Chloro-1-Propanol Ester Actinocin
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Figure 4.3.2(a)- Reaction done to form β-ring heterocycle in model compound 3Chloro-1-Propanol Ester Actinocin
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Figure 4.3.2(b)- TIC of product mixture from the reaction described in Figure 4.3.2(a)
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This Total Ion Chromatogram highlights a peak at 15.603 min.

Figure 4.3.2(c)- HRMS spectrum of peak at 15.603 min
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Figure 4.3.2(d)- UV spectra of peak at 15.603 min
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Figure 4.3.2(e)- TIC of product mixture from the reaction described in Figure 4.3.2(a)
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This Total Ion Chromatogram highlights a peak at 17.392 min.

Figure 4.3.2(f)- HRMS spectrum of peak at 17.392 min
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Figure 4.3.2(g)- UV spectra of peak at 17.392 min
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Figure 4.3.2(h)- UV spectra of peak at 15.603 min (black) overlaid with UV spectra of peak at 17.392 min (red)
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Chapter 5: Results Summary and Future Directions
5.1 Results Summary
This dissertation began with the goals to validate the biological activity of the novel
actinomycin structure, actinomycin Y5, and to expand upon it’s antibiotic potential.
However, in the quest to achieve those goals we learned several things about the physical
properties of the actinomycin aromatic core, the breadth of actinomycin familial diversity
produced by two strains of Streptomyces species, the biological activity of the newly
discovered actinomycin compounds, and the conditions under which β-ring heterocycle
formation can instigated. The results from this quest will be summarized here and their
implications discussed below.
Firstly, the actinomycin core appears reactive enough to perform an SN2 style of
nucleophilic attack upon the 4-chlorothreonine unit found in actinomycins such as Y1 and
Z5. Interestingly, it would appear that the 2-NH2 aniline position of the methyl actinocin
model compound has two acid dissociation constants, though one is much more relevant
to the formation of the heterocycle found in actinomycin Y5. With an upper bound pKa of
8.429, methyl actinocin is deprotonated in neutral water approximately once per fifty
molecules. This result answers a question related to the motivation to develop this model:
if the 2-NH2 position of the actinomycin core was reactive enough to form the β-ring
heterocycle found in actinomycin Y5 via an SN2 mechanism, why did the compound not
occupy a larger share of the actinomycins produced in the Y-family? This level of reactivity
would explain this paradox; such a nucelophic attack would be a rather uncommon
occurrence. Furthermore, the noticeable fluctuation in UV absorption between 300-350 nm
of the methyl actinocin at pH’s above the calculated upper bound pKa proved to validate
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an observed oddity in some of the newly isolated actinomycins (Figure 2.3.1 and Figure
2.3.2). We attributed this change in UV absorption to a change in state at the 2-NH2 position
of methyl actinocin.
Once it was determined that the β-ring heterocycle of actinomycin Y5 could be
formed by nucleophilic attack, it was important to rule out any enzymatic alternatives.
Through a comparative analysis of the actinomycin G, Y, and Z gene clusters, there appears
to be no obvious inclusion or exclusion of genomic data that would be responsible for the
formation of a new actinomycin structural motif. The actinomycin G, Y and Z clusters were
chosen for this comparative analysis because they were the three actinomycin families that
utilized a 4-chlorothreonine component in the β-ring depsipeptide. Because of this genome
similarity between the actinomycin G, Y, and Z clusters, we hypothesized that there were
undiscovered actinomycin Z family members that would contain a β-ring heterocycle.
Based on HRMS and UV absorption maxima between 300-320 nm, we believe that we
have isolated not only actinomycin that contain our motif of interest but also actinomycins
that contain an oxime at the 2-NH2 position (Figures 3.4.5(a)-(k) and Figures 3.4.11(a)(g)). Such an actinomycin structure would not be without precedent: Wang et al. discovered
the neoactinomycins, which contain a nitrogen-oxygen bond at that position as a result of
an intracellular reaction with pyruvate and Brockmann et al. was able to synthesize an
actinomycin analogue containing a similar motif.2,
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Surprisingly, in our search for

actinomycin Y5 from the producing Streptomyces GÖ-GS12, we found a second
actinomycin Y family member containing a β-ring heterocycle: actinomycin Y6, which,
curiously, contains both the structural motif of interest but also the rearranged β-ring core.
This discovery challenged the perceived mechanism of formation of the β-ring heterocycle
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as there is no chlorine electrophile for the 2-NH2 group to attack in an SN2 manner after
the β-ring core undergoes its rearrangement via two-fold acyl shift.72
These newly isolated actinomycins were tested for their biological activity against
several types of bacteria and cancers. Those activities were compared to that of
actinomycin D against the same cell types to form a ratio of biological activity that could
be compared to other actinomycins who’s biological activity was tested at different times
against different cell lines (Tables 1.3, 4.3.1 and 4.3.2). This comparison led us to the
conclusion that the β-ring heterocycle did something unique to the activity of those
actinomycins containing this motif. Using a Gaussian optimization model, we predicted
that the tighter, more confined shape of the β-ring heterocycle-containing compounds was
responsible for this activity.74 This gave us hope that the antibacterial potential for
actinomycin Y5 was not a result of experimental design but could be a unique property of
the molecule. However, in our hands, actinomycin Y6 showed mild biological activity
against both gram positive bacteria and the cancers tested instead of the antibacterial
selectivity observed in the initial biological screening of actinomycin Y5.37 Furthermore,
the biological activities observed in the actinomycin Z compounds were similar to those
observed in the actinomycin Y family and consistent with all of the structure-activity
relationship data compiled in Section 1.3 with one notable exception: compounds that we
believe contain β-ring heterocycles did not show improved antibacterial activity compared
to their cytotoxicity. These studies are being repeated to confirm this activity.
The discrepancy in activity between actinomycins Y5 and Y6 as well as the
actinomycin Z compounds predicted to posses a β-ring heterocycle or have an oxime at the
2-NH2 position posed a problem: if we were interested in developing these compounds as
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potential therapeutics, what are the conditions under which we can make one of these
structures but not the others? Can the β-ring heterocycle be formed under mild chemical
conditions—like those found within a bacterial cell—at all? The model compound we
synthesized—3-chloro-1-propanol ester actinocin—was found to cyclize in the presence
of cesium carbonate, sodium iodide, and mild heat, which would likely indicate that this
SN2 cyclization could occur naturally, albeit more slowly. We then applied those conditions
to the actinomycin Y1 and Z5 compounds we isolated; the results of those experiments are
not yet available.
All of this data taken together—the pKa of the actinomycin core, the gene cluster
similarity between families of actinomycin, the novel compounds discovered, and the
cyclization conditions observed in the model 3-chloro-1-propanol ester actinocin—leads
us to the conclusion that the actinomycin Y and Z gene clusters produce a single product
and the familial diversity observed in culture is due to the reactivity of the actinomycin
core. This conclusion is visualized in Figure 5.1.1.
Much of the rationale for this conclusion came when analyzing the HRMS and UV
absorption data for the isolated actinomycin Z compounds (Figures 3.3.5(a)-3.3.13(m)).
As Section 3.3 articulates, the compounds were isolated as pure peaks from the semipreparative HPLC; these compounds were stored in a mixture of acetonitrile and water
until they were lyophilized and then characterized. During their final characterization, these
products would appear to have broken down into several products no matter how isolated
and pure the peak was at the time of its collection. Furthermore, this breakdown often
occurred in predictable ways and almost always included an isolate with the mass and UV
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signature indicative of a β-ring heterocycle containing compound, setting up compounds
like actinomycin Y5 as an unstable intermediate in this degradation pathway.
Another piece of evidence supporting this conclusion is the formation of
actinomycin Y6. As alluded to in Section 3.3, actinomycin Y6 is likely formed after the
Michael-like attack on the 4-position of the α,β-unsaturated amide, which was made after
the elimination of the newly exposed hydroxyl group generated after the rearrangement of
the β-ring core. The difference in structure between 4-chlorothreonine containing
actinomycins and actinomycins with a rearranged core—both of which form a β-ring
heterocycle—is pronounced as shown in Figure 3.3.3, and Figure 3.3.4 reducing the
likelihood a single enzyme could perform both of these reactions. The difference in
electrophile in each of these cases is also vastly different. Therefore, the driving force
behind both of these β-ring heterocycle formations is the nucleophilicity of the 2-NH2
position within the actinomycin core and not the electrophilicity of the group being
attacked.
The final piece of evidence presented here to support this conclusion is that we have
observed that these heterocyclic products are not a large portion of the metabolites
collected from the production of this gene cluster, it is reasonable to assume that there is
no scripted process for their manufacture. Furthermore, these heterocyclic products are not
as active as the halogenated family members, indicating compounds like actinomycin Y5
and Y6 would do a worse job at protecting the bacterial producer than a compound like
actinomycin Y1. Therefore, there would be little incentive for the producing strain to make
the heterocyclic actinomycins intentionally. There also appears to be no obvious gene
candidate to make an enzyme that could perform this chemistry
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Figure 5.1.1- Proposed Reactive Pathway Leading to Actinomycin Familial Diversity Within Actinomycin G, Y and Z
Families
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5.2 Future Directions
The goal at the inception of this research was to confirm the biological activity of
actinomycin Y5 and to determine if a novel mechanism of action/therapeutic target was
responsible for its unique activity. However, due to our inability to isolate pure actinomycin
Y5, we were forced to attempt to create our own and to analyze the possible sources of our
shortcomings. The areas of analysis we chose to pursue were the physical properties of the
actinomycin core (Chapter 2), the gene clusters of the actinomycin Y-family producer and
the closely related actinomycin Z-family producer as well as the secondary metabolites
produced by each (Chapter 3), and the conditions under which the formation of the β-ring
heterocycle could occur (Chapter 4). Each of these analyses attempted to answer a logical
series of questions: is it possible for the actinomycin core to preform an SN2 attack on the
4-chlorothreonine residue, is there an enzymatic explanation for the formation of this
structural motif, and can actinomycin Y5 be made with some light medicinal chemistry
from what is believed to be the primary product of each of the actinomycin Y and
actinomycin Z gene clusters?
Outlined in Section 5.1 are what we believe the answers to these questions to be
but in our search for these answers, new areas of research have emerged. For example, the
discovery that the 2-NH2 position on the actinomycin core is reactive allows the possibility
to create new actinomycin derivatives. Though many derivatives were made between the
years 1959-72, none of them were made with a purpose beyond probing the structureactivity relationship of the various components of the actinomycin molecule.22-23, 27-29, 32
With advancements in solid-phase synthesis increasing the yields of peptide syntheses that
require multiple steps and with the total synthesis of actinomycin D already known, there
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is a tremendous opportunity to attach chemical handles or other reactive groups to this site
in a totally synthetic or semi-synthetic manner.79-81 One opportunity to utilize this handle
would be to immobilize further the DNA-RNA polymerase complex that actinomycin halts
as its mechanism of action; this immobilization could aid in obtaining a crystal structure
of how the three entities interact, something that has yet to be obtained and one of the few
remaining mysteries of how actinomycin interacts with DNA.14, 82
Another area of study that this research could be applied to is the full and accurate
characterization of the actinomycin Y, Z, and G gene clusters. Though most of the
actinomycin gene cluster has been characterized, there are several enzymes of interest
whose function is not understood. For example, one of the most famous mysteries
concerning the biosynthesis of actinomycin has been the inability to identify the gene
responsible for the production of the enzyme that unifies the α- and β-rings of the molecule.
It has been previously reported that the actinomycin chromophore can be synthesized by a
phenoxazinone synthase; however no gene within the cluster exhibits enough sequence
similarity to this class of enzyme to be classified as such.44-45, 47, 83-84 Furthermore, several
of the tailoring enzymes found in the actinomycin G, Y and Z clusters—known as acmG69, acmY14-17, and acmZ14-17 in their respective gene clusters—have not had their
putative functions identified, though some preliminary work has been reported on this
group. For instance, acmG9 and its acmY17 and Z17 homologues have all been
characterized as non-heme α-ketogluterate dependent halogenases and acmG8 and its
acmY16 and Z16 homologues cytochrome P450 enzymes; these assignments were
confirmed to be responsible for the chlorination and hydroxylation, respectively, of the βring threonine via knockout and complementation experiments.47 However, in those same
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experiments, the knockout of either one of these genes abolished the supposed product of
the other. There could be several explanations for this finding. The class of halogenase of
which acmG9, acmY17, and acmZ17 belong to has been show to both halogenate and
hydroxylate under certain conditions.85 It is possible this enzyme’s promiscuity is
responsible for the generation of both modified threonine units and is enabled by acmG8
and homologues. It is possible these enzymes form and complex and are inactive without
one another or are not recruited to the NRPS by some X-domain mechanism without the
combination of the two; no in vitro assays have been done to confirm the activity of these
enzymes.86 In Section 5.1, we propose an alternative theory to how familial diversity
among these actinomycin families is achieved that coincides with all previously observed
data. If we are correct, then it is likely at least one of these enzymes is performing a function
that was not previously predicted. Only further testing will illuminate this biosynthetic
conundrum. Additionally, study of acmG6 and 7 and their Y- and Z family homologues Y
and Z14-15 have hardly been studied at all. An acmG7 knockout was shown to abolish
production of actinomycin but a homologue is not present in all actinomycin gene
clusters.45, 47 It was believed to have been involved in the oxidations of the actinomycin
proline residues, although that seems unlikely to halt all actinomycin production should it
be absent given the trivial nature of the proline residues. It carries with it the vague
annotation of being a member of the SDR_c superfamily of enzymes, which have been
show to perform various types of redox chemistry.87-88 No knockout was made for acmg6
and homologues and it is most similar to a bifunctional phosphoglucose/phosphomanose
isomerase. Given the lack of sugar molecules attached to the final compound, this enzyme
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is likely performing an unpredicted function during the biosynthesis of these compounds.
There is plenty to learn about these tailoring enzymes.
Additionally, another aspect of actinomycin scaffold formation that requires
investigation is the reported structure of actinomycin G5; this compound is reported to
contain a β-ring heterocycle similar to actinomycin Y5 but with an oxygen serving as the
heteroatom instead of nitrogen.36 Currently, the only piece of evidence to support the claim
of a different heteroatom between actinomycin G5 and actinomycin Y5 is the difference in
carbon NMR at β-ring position HThr-4 (δC 68.48 for G5 and 45.3 for Y5).35-36 This would
indicate the carbon at this position in actinomycin G5 is adjacent to a more electronegative
atom causing greater electronic deshielding, which would imply the presence of an oxygen
atom as opposed to a nitrogen. A possible mechanism for this type of spontaneous
heterocycle formation is shown in Figure 5.2.1. However, this mechanism relies on the
deprotonation of the hydroxyl group at β-ring position HThr-4 by the 2-NH2 aniline group,
a phenomenon that seems extremely unlikely given the difference in basicity between the
2-NH2 aniline and the hydroxyl group (pKa 8.429 vs ~16) and in the time spent working
with the actinomycin Y actinomycin Z families, we have not yet come across a congener
containing this structural motif, which we would expect given the closeness of these
families to actinomycin G both genetically and structurally. We would like confirm the
uniqueness in structure of actinomycin G5 ourselves.
The actinomycins have also recently been used in a salamander tail regeneration
assay (Figure 5.2.2) similarly to previously published assay results.89 The assay showed
that actinomycins D, Y1, and Z1 inhibited regenerative growth of cut salamander tails at a
10 µM concentration but that actinomycin Y6 did not. This provides some anecdotal
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evidence that the doubly hydroxylated actinomycin Z1 does make it past the cellular
membrane and that actinomycin Y6 does not bind DNA. Since we hypothesized that overly
hydroxylated actinomycins might have decreased activity due to a lack of availability at
the site of action and that the formation of the β-ring heterocycle would rescue some of the
activity lost by the rearrangement of the β-ring core in actinomycin Y6, it is worth pursuing
experiments that challenge our initial hypothesis.
One final aspect of this work that requires further exploration—and might be the
most relevant topic to the development of a new medication—is the stabilization of the βring heterocycle and the determination of how the constricted shape interacts with DNA.
There have been numerous studies examining the structure-activity relationships between
various additions to the actinomycin scaffold. It has become clear through the work shown
here in Section 4.3 and the works collected in Section 1.3 that additional oxidations to the
proline and threonine residues greatly reduce the biological activity of the compounds; a
rearrangement to the β-ring core appears to have a similar effect.2, 34-35, 37-38 This reduced
activity could be caused by inefficient binding to DNA, an inability for the more polar
compounds to traverse the cellular membrane, the addition of chemical handles that could
be acted upon by possible resistance mechanisms, or some combination of all three.90
However, the addition of a chlorine group to the β-threonine does not appear to diminish
the compound’s efficacy relative to actinomycin D. Interestingly, the activity of the
rearranged actinomycins can be rescued by forming a β-ring heterocycle, which—
according to a Gaussian optimization program—readjusts the binding plane of the
rearranged actinomycins to be similar to that of actinomycin D.37, 74
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The secondary amine linkage that forms the β-ring heterocycle appears to be acid
labile, which would make it unlikely to survive the various conditions a drug is exposed to
in vivo.37 Fortunately, it would appear that the three dimensional shape of the actinomycin
molecule to be more important for activity than the heteroatoms away from the actinocin
core. This gives us the freedom to install other heteroatoms or groups in place of the acidlabile amine to maintain the structure the β-ring heterocycle creates. For example,
phosphate can be inserted in place of nitrogen to utilize its ability to form five stable bonds,
much in the same way that sarin gas binds to acetocholinesterase (Figure 5.2.3).91-92
Another alternative would be to remove the heteroatom from the formation of this
additional β-ring by utilizing olefin metathesis (Figure 5.2.4).93 These pathways could be
used to expand on contract the size the additional ring as well. This would provide
numerous insights into the behaviors of this new, constricted actinomycin, while also
making our potential drug more stable.
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Figure 5.2.1- Possible Mechanism to Explain the Structure of Actinomycin G5
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Figure 5.2.3- Sarin-like Mechanism and Incorporation in Actinomycin Scaffold
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